Patent Application
20180256699
The Sequence Listing written in file 48932-524001WO_ST25.TXT, created on Dec. 8, 2015, 129,614 bytes, machine format IBM-PC, MS-Windows operating system, is hereby incorporated by reference in its entirety for all purposes.
Whooping cough is a highly infectious disease caused primarily by the bacteria Bordetella pertussis. While incidence has dropped dramatically since the initiation of widespread vaccination programs using killed bacteria in the 1940s, in recent years rates have rebounded dramatically, reaching a 60-year high in the US in 2012 (1-3). This trend is especially troubling for unimmunized infants, who are most susceptible to the disease and exhibit the highest rates of morbidity and mortality. Modified vaccination strategies, including booster immunization of adolescents, adults and pregnant women, have been implemented to reduce transmission to neonates.
This increase in disease incidence coincides with the switch from whole cell to acellular vaccines in the 1990s, and has been attributed to several factors, including increased awareness, mismatch between vaccine and circulating strains, a Th1/Th2 immune response instead of the more effective Th1 response and a shorter duration of protection conferred by acellular vaccines (4). Recently, Warfel et al. demonstrated that acellular vaccines protect against disease symptoms but not subclinical infection and transmission in a novel non-human primate model (5). Taken together, these data provide a compelling argument for modification of the current vaccine.
Currently licensed acellular vaccines contain chemically detoxified pertussis toxin (PTx) and up to four surface adhesins, including filamentous hemagglutinin, pertactin and fimbriae 2/3. Exciting approaches in development to enhance vaccine-mediated protective immunity include a genetically attenuated B. pertussis for intranasal delivery (6); nanoparticle formulations including purified antigens and novel adjuvant formulations (7); as well as inclusion of additional highly conserved antigens in the current vaccine (8,9). A strong candidate for inclusion in any of these is the adenylate cyclase toxin (ACT) which aids in immune evasion and is produced by three closely related Bordetella species, including B. pertussis, B. parapertussis, and B. bronchiseptica (10,11).
ACT-deficient Bordetella strains have shown significantly compromised colonization and persistence in various mouse models (12-14), while some hypervirulent strains express higher ACT levels (15). Moreover, active or passive immunization with polyclonal anti-ACT antibodies protected mice against lethal respiratory challenges by B. pertussis and B. parapertussis (15) and shortened the period of bacterial colonization in the respiratory tract (16). Finally, natural infection of humans results in a strong anti-ACT antibody response (17).
ACT is a large, ˜177 kDa protein, consisting of two functionally discrete regions: the catalytic domain (residues 1-385), and a pore-forming or hemolysin region which is part of the larger repeat in toxin (RTX) family, represented in >250 bacterial strains (
Despite evidence indicating ACT is a protective antigen, few neutralizing antibodies have been described and the location of neutralizing epitopes remains unclear. Moreover, ACT is prone to aggregation and degradation when produced by Bordetella or recombinantly by E. coli, precluding its inclusion in current acellular vaccine formulations (28). Therefore, we aimed to identify neutralizing antibodies and their domain specificity and determine whether any single domain, possessing desirable expression and protein stability characteristics, can recapitulate the antibody responses induced by the holo-toxin.
The present disclosure provides antibodies specific for a single domain of ACT that recapitulate the antibody responses induced by the holo-toxin and provide a dominant neutralizing antibody response. Mice were immunized with ACT, and the resulting antibodies were screened for binding to purified ACT. The vast majority of unique antibodies identified bound the C-terminal repeat-in-toxin (RTX) domain. Representative antibodies binding two non-overlapping, neutralizing epitopes in the RTX domain prevent ACT association with J774A.1 macrophages and soluble αMβ2 integrin, suggesting that these antibodies inhibit the ACT-receptor interaction. Sera from mice immunized with the RTX domain showed similar neutralizing activity as ACT-immunized mice, indicating that this domain induced an antibody response similar to that induced by ACT. These data show that RTX can elicit neutralizing antibodies, which can in turn be used to treat Bordetella infection.
Provided herein are antibodies that compete for binding to the RTX domain of Bordetella ACT with an antibody comprising sequences selected from the group consisting of: light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:1 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:2; light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:3 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:4; light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:5 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:6; light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:7 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:9; light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:9 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:10; and light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:11 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:12. In embodiments, the antibody comprises sequences selected from the group consisting of: light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:1 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:2; light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:3 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:4; light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:5 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:6; light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:7 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:9; light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:9 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:10; and light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:11 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:12. In embodiments, the antibody comprises sequences selected from the group consisting of: light chain variable region sequence of SEQ ID NO:1 and heavy chain variable region sequence of SEQ ID NO:2; light chain variable region sequence of SEQ ID NO:3 and heavy chain variable region sequence of SEQ ID NO:4; light chain variable region sequence of SEQ ID NO:5 and heavy chain variable region sequence of SEQ ID NO:6; light chain variable region sequence of SEQ ID NO:7 and heavy chain variable region sequence of SEQ ID NO:9; light chain variable region sequence of SEQ ID NO:9 and heavy chain variable region sequence of SEQ ID NO:10; and light chain variable region sequence of SEQ ID NO:11 and heavy chain variable region sequence of SEQ ID NO:12.
In embodiments, the antibody comprises light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:1 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:2. In embodiments, the antibody comprises light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:3 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:4. In embodiments, the antibody comprises light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:5 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:6. In embodiments, the antibody comprises light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:7 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:9. In embodiments, the antibody comprises light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:9 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:10. In embodiments, the antibody comprises light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:11 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:12.
Also provided herein are antibodies that compete for binding to the RTX domain of Bordetella ACT with an antibody comprising sequences selected from the group consisting of: light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:13 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:14; light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:15 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:16; and light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:17 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:18. In embodiments, the antibody comprises sequences selected from the group consisting of CDR1, CDR2, and CDR3 sequences of SEQ ID NO:13 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:14; light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:15 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:16; and light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:17 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:18. In embodiments, the antibody comprises sequences selected from the group consisting of light chain variable region sequence of SEQ ID NO:13 and heavy chain variable region sequence of SEQ ID NO:14; light chain variable region sequence of SEQ ID NO:15 and heavy chain variable region sequence of SEQ ID NO:16; and light chain variable region sequence of SEQ ID NO:17 and heavy chain variable region sequence of SEQ ID NO:18.
In embodiments, the antibody comprises light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:13 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:14. In embodiments, the antibody comprises light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:15 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:16. In embodiments, the antibody comprises light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:17 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:18.
In embodiments, the antibody binds the RTX domain of Bordetella ACT with a Kd of 0.01-100 nM, e.g., 0.1-100 nM, 0.5-50 nM, or 0.1-20 nM. In embodiments, the antibody is humanized, e.g., with 1, 2, 3, 4, 5, 6, 7, or 8 framework regions derived from a human antibody. In embodiments, the antibody further comprises a constant region, e.g., derived from a human antibody.
In embodiments, the antibody is a single chain antibody. In embodiments, the antibody is an Fab, Fab′, or F(ab′)2. In embodiments, the antibody is a humanized single chain antibody. In embodiments, the antibody is a humanized Fab, Fab′, or F(ab′)2. In embodiments, the single chain antibody comprises a light chain variable region (optionally humanized), a linker consisting of 4-100 amino acids, and a heavy chain variable region (optionally humanized). In embodiments, the linker is 4-40 amino acids, e.g., 10-30, or 16-24 amino acids.
In embodiments, the antibody is attached to a detectable label, e.g., a fluorescent label or affinity tag. In embodiments, the antibody is attached to a stabilizing agent, e.g., PEG or PEG derivative.
Provided herein are methods for diagnosing a Bordetella infection in an individual comprising contacting a biological sample from the individual with an antibody as described above; determining if the antibody binds a component of the biological sample (i.e., if the antibody binds Bordetella ACT in the biological sample); and diagnosing Bordetella infection in the individual when the antibody binds a component of the biological sample. In embodiments, the biological sample is saliva, mucus, sputum, blood (or serum), taken from a nasal pharangeal swab or biopsy, a cellular sample, or cell lysate. In embodiments, the determining is carried out using an ELISA (e.g., a sandwich ELISA using antibodies specific for different epitopes of ACT).
Further provided are pharmaceutical compositions comprising an antibody as described above and a pharmaceutically acceptable excipient. In embodiments, the pharmaceutical composition comprises more than one antibody as described above, e.g., antibodies that bind different epitopes of the RTX domain. In embodiments, the pharmaceutical composition further comprises an antibacterial agent.
Provided are methods for treating or preventing Bordetella infection in an individual comprising administering a pharmaceutical composition as described above to the individual, thereby treating or preventing Bordetella infection in an individual. In embodiments, the administering is to a mucosal surface, e.g., in a nasal or oral aerosol. In embodiments, the administering is parenteral, e.g., intraperitoneal, intravenous, or subcutaneous. In embodiments, the individual is a human. In embodiments, the pharmaceutical composition is administered more than once. In embodiments, the pharmaceutical composition is administered within about two weeks of exposure to Bordetella, e.g., within one week, three days, or one day from exposure. In embodiments, the pharmaceutical composition is administered with an additional therapeutic agent, e.g., an antibacterial agent, either simultaneously or separately.
In one aspect a vaccine composition is provided. The composition includes a recombinant Bordetella adenylate cyclase toxin polypeptide consisting essentially of a sequence corresponding to amino acid residues 700-1706 of Bordetella adenylate cyclase toxin protein or an immunogenic fragment thereof and a pharmaceutically acceptable vaccine excipient.
In one aspect a method for immunizing a subject in need thereof against Bordetella pertussis is provided. The method includes administering to the subject an effective amount of the vaccine as provided herein including embodiments thereof.
In another aspect, a method of preventing or treating whooping cough in a subject in need thereof is provided. The method includes administering to the subject a therapeutically effective amount of the vaccine as provided herein including embodiments thereof.
M1H5 has light and heavy chain variable region sequences of SEQ ID NOs:1 and 2, respectively. M2C2 has light and heavy chain variable region sequences of SEQ ID NOs:3 and 4, respectively. M1F10 has light and heavy chain variable region sequences of SEQ ID NOs:5 and 6, respectively. M1E12 has light and heavy chain variable region sequences of SEQ ID NOs:7 and 8, respectively. M2F9 has light and heavy chain variable region sequences of SEQ ID NOs:9 and 10, respectively. M2B5 has light and heavy chain variable region sequences of SEQ ID NOs:11 and 12, respectively. M1E2 has light and heavy chain variable region sequences of SEQ ID NOs:13 and 14, respectively. M1H1 has light and heavy chain variable region sequences of SEQ ID NOs:15 and 16, respectively. M2B10 has light and heavy chain variable region sequences of SEQ ID NOs:17 and 18, respectively.
M1H5 binds RTX751 with an affinity of ˜1.6 nM, and inhibits ACT-receptor interaction with IC50=2.5 nM in J774. A cell neutralization (ACT=125 ng/mL). M2B10 binds RTX751 with an affinity of ˜1.2 nM, and inhibits ACT-receptor interaction with an IC50=6.0 nM. M2C2 binds RTX751 with an affinity of ˜1.5 nM, and inhibits ACT-receptor interaction with an IC50=8.1 nM. IC50 values were measured in J774A.1 macrophage cell line intoxication assay with 125 ng/mL ACT (0.7 nM).
The adenylate cyclase toxin (ACT) is a multifunctional virulence factor secreted by Bordetella species. Upon interaction of its C-terminal hemolysin moiety with the cell surface receptor αMβ2 integrin, the N-terminal cyclase domain translocates into the host cell cytosol where it rapidly generates supra-physiological cAMP concentrations, which inhibit host cell anti-bacterial activities. Although ACT has been shown to induce protective immunity in mice, it is not included in any current acellular pertussis vaccines due to protein stability issues and poor understanding of its role as a protective antigen.
Provided herein are neutralizing antibodies that specifically bind to ACT, in particular the RTX (repeat in toxin) domain. Such antibodies can be used for passive immunotherapy and diagnosis of Bordetella infections. Further provided herein are highly protective vaccines including recombinant Bordetella adenylate cyclase toxin polypeptides corresponding to C-terminal fragments of ACT and uses thereof for the treatment and prevention of whooping cough.
Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by a person of ordinary skill in the art. See, e.g., Lackie, D
The term “antibody” refers to a polypeptide comprising a framework region from an immunoglobulin gene, or fragments thereof, that specifically bind and recognize an antigen, e.g., β8, a particular cell surface marker, or any desired target. Typically, the “variable region” contains the antigen-binding region of the antibody (or its functional equivalent) and is most critical in specificity and affinity of binding. See Paul, Fundamental Immunology (2003). The term includes antibody fragments and antibody variants that specifically bind to the antigen.
An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one “light” (about 25 kD) and one “heavy” chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (VL) and variable heavy chain (VH) refer to these light and heavy chains respectively.
An “isotype” is a class of antibodies defined by the heavy chain constant region. Immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the isotype classes, IgG, IgM, IgA, IgD and IgE, respectively.
Antibodies can exist as intact immunoglobulins or as any of a number of well-characterized fragments that include specific antigen-binding activity. Such fragments can be produced by digestion with various peptidases. Pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab)′2, a dimer of Fab which itself is a light chain joined to VH-CH1 by a disulfide bond. The F(ab)′2 may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the F(ab)′2 dimer into an Fab′ monomer. The Fab′ monomer is essentially Fab with part of the hinge region (see Fundamental Immunology (Paul ed., 3d ed. 1993). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized de novo either chemically or by using recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies, or those synthesized de novo using recombinant DNA methodologies (e.g., single chain Fv) or those identified using phage display libraries (see, e.g., McCafferty et al., Nature 348:552-554 (1990)).
A “monoclonal antibody” refers to a clonal preparation of antibodies with a single binding specificity and affinity for a given epitope on an antigen. A “polyclonal antibody” refers to a preparation of antibodies that are raised against a single antigen, but with different binding specificities and affinities.
As used herein, “V-region” refers to an antibody variable region domain comprising the segments of Framework 1, CDR1, Framework 2, CDR2, Framework 3, CDR3, and Framework 4. These segments are included in the V-segment as a consequence of rearrangement of the heavy chain and light chain V-region genes during B-cell differentiation.
As used herein, “complementarity-determining region (CDR)” refers to the three hypervariable regions in each chain that interrupt the four “framework” regions established by the light and heavy chain variable regions. The CDRs are primarily responsible for binding to an epitope of an antigen. The CDRs of each chain are typically referred to as CDR1, CDR2, and CDR3, numbered sequentially starting from the N-terminus, and are also typically identified by the chain in which the particular CDR is located. Thus, a VH CDR3 is located in the variable domain of the heavy chain of the antibody in which it is found, whereas a VL CDR1 is the CDR1 from the variable domain of the light chain of the antibody in which it is found.
The sequences of the framework regions of different light or heavy chains are relatively conserved within a species. The framework region of an antibody, that is the combined framework regions of the constituent light and heavy chains, serves to position and align the CDRs in three dimensional space.
The amino acid sequences of the CDRs and framework regions can be determined using various well known definitions in the art, e.g., Kabat, Chothia, international ImMunoGeneTics database (IMGT), and AbM (see, e.g., Johnson et al., supra; Chothia & Lesk, (1987) J. Mol. Biol. 196, 901-917; Chothia et al. (1989) Nature 342, 877-883; Chothia et al. (1992) J. Mol. Biol. 227, 799-817; Al-Lazikani et al., J. Mol. Biol 1997, 273(4)). Definitions of antigen combining sites are also described in the following: Ruiz et al. Nucleic Acids Res., 28, 219-221 (2000); and Lefranc Nucleic Acids Res. January 1; 29(1):207-9 (2001); MacCallum et al., J. Mol. Biol., 262: 732-745 (1996); and Martin et al, Proc. Natl Acad. Sci. USA, 86, 9268-9272 (1989); Martin, et al, Methods Enzymol., 203: 121-153, (1991); Pedersen et al, Immunomethods, 1, 126, (1992); and Rees et al, In Sternberg M. J. E. (ed.), Protein Structure Prediction. Oxford University Press, Oxford, 141-172 1996).
A “chimeric antibody” is an antibody molecule in which (a) the constant region, or a portion thereof, is altered, replaced or exchanged so that the antigen binding site (variable region, CDR, or portion thereof) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody (e.g., an enzyme, toxin, hormone, growth factor, drug, etc.); or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region having a different or altered antigen specificity (e.g., CDR and framework regions from different species).
The antibody binds to an “epitope” on the antigen. The epitope is the specific antibody binding interaction site on the antigen, and can include a few amino acids or portions of a few amino acids, e.g., 5 or 6, or more, e.g., 20 or more amino acids, or portions of those amino acids. In some cases, the epitope includes non-protein components, e.g., from a carbohydrate, nucleic acid, or lipid. In some cases, the epitope is a three-dimensional moiety. Thus, for example, where the target is a protein, the epitope can be comprised of consecutive amino acids, or amino acids from different parts of the protein that are brought into proximity by protein folding (e.g., a discontinuous epitope). The same is true for other types of target molecules that form three-dimensional structures.
The term “specifically bind” refers to a molecule (e.g., antibody, polypeptide or fragment thereof) that binds to a target with at least 2-fold greater affinity than non-target compounds, e.g., at least 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 25-fold, 50-fold, or 100-fold greater affinity. For example, an antibody that specifically binds ACT will typically bind to ACT with at least a 2-fold greater affinity than a non-ACT target.
The term “binds” with respect to a particular target (e.g., ACT or αMβ2 integrin) typically indicates that an antibody or recombinant Bordetella adenylate cyclase toxin polypeptide as provided binds a majority of the targets in a pure population of those targets. For example, an antibody that binds a given cell type typically binds to at least 2/3 of the cells in a population of the indicated cells (e.g., 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%). One of skill will recognize that some variability will arise depending on the method and/or threshold of determining binding.
As used herein, a first antibody, or an antigen-binding portion thereof, “competes” for binding to a target with a second antibody, or an antigen-binding portion thereof, when binding of the second antibody with the target is detectably decreased in the presence of the first antibody compared to the binding of the second antibody in the absence of the first antibody. The alternative, where the binding of the first antibody to the target is also detectably decreased in the presence of the second antibody, can, but need not be the case. That is, a second antibody can inhibit the binding of a first antibody to the target without that first antibody inhibiting the binding of the second antibody to the target. However, where each antibody detectably inhibits the binding of the other antibody to its cognate epitope or ligand, whether to the same, greater, or lesser extent, the antibodies are said to “cross-compete” with each other for binding of their respective epitope(s). Both competing and cross-competing antibodies are encompassed by the present invention. The term “competitor” antibody can be applied to the first or second antibody as can be determined by one of skill in the art. In some cases, the presence of the competitor antibody (e.g., the first antibody) reduces binding of the second antibody to the target by at least 10%, e.g., 20%, 30%, 40%, 50%, 60%, 70%, 80%, or more, e.g., so that binding of the second antibody to target is undetectable in the presence of the first (competitor) antibody.
Similarly, a first recombinant polypeptide as provided herein “competes” for binding to a target (αMβ2 integrin) with an antibody or a second recombinant polypeptide, when binding of the antibody or second recombinant polypeptide with the target is detectably decreased in the presence of the first recombinant polypeptide compared to the binding of the antibody or second polypeptide in the absence of the first recombinant polypeptide.
“Nucleic acid” refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form, and complements thereof. The term “polynucleotide” refers to a linear sequence of nucleotides. The term “nucleotide” typically refers to a single unit of a polynucleotide, i.e., a monomer. Nucleotides can be ribonucleotides, deoxyribonucleotides, or modified versions thereof. Examples of polynucleotides contemplated herein include single and double stranded DNA, single and double stranded RNA (including siRNA), and hybrid molecules having mixtures of single and double stranded DNA and RNA.
The words “complementary” or “complementarity” refer to the ability of a nucleic acid in a polynucleotide to form a base pair with another nucleic acid in a second polynucleotide. For example, the sequence A-G-T is complementary to the sequence T-C-A. Complementarity may be partial, in which only some of the nucleic acids match according to base pairing, or complete, where all the nucleic acids match according to base pairing.
A variety of methods of specific DNA and RNA measurements that use nucleic acid hybridization techniques are known to those of skill in the art (see, Sambrook, Id.). Some methods involve electrophoretic separation (e.g., Southern blot for detecting DNA, and Northern blot for detecting RNA), but measurement of DNA and RNA can also be carried out in the absence of electrophoretic separation (e.g., quantitative PCR, dot blot, or array).
The words “protein”, “peptide”, and “polypeptide” are used interchangeably to denote an amino acid polymer or a set of two or more interacting or bound amino acid polymers. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers, those containing modified residues, and non-naturally occurring amino acid polymer.
The term “amino acid” refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function similarly to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ-carboxyglutamate, and 0-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, e.g., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs may have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions similarly to a naturally occurring amino acid.
Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.
“Conservatively modified variants” applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical or associated, e.g., naturally contiguous, sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode most proteins. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to another of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are “silent variations,” which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes silent variations of the nucleic acid. One of skill will recognize that in certain contexts each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, silent variations of a nucleic acid which encodes a polypeptide is implicit in a described sequence with respect to the expression product, but not with respect to actual probe sequences.
As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a “conservatively modified variant” where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention. The following amino acids are typically conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)).
The terms “identical” or “percent identity,” in the context of two or more nucleic acids, or two or more polypeptides, refer to two or more sequences or subsequences that are the same or have a specified percentage of nucleotides, or amino acids, that are the same (i.e., about 60% identity, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters, or by manual alignment and visual inspection. See e.g., the NCBI web site at ncbi.nlm.nih.gov/BLAST. Such sequences are then said to be “substantially identical.” This definition also refers to, or may be applied to, the compliment of a nucleotide test sequence. The definition also includes sequences that have deletions and/or additions, as well as those that have substitutions. As described below, the algorithms can account for gaps and the like. Typically, identity exists over a region comprising an antibody epitope, or a sequence that is at least about 25 amino acids or nucleotides in length, or over a region that is 50-100 amino acids or nucleotides in length, or over the entire length of the reference sequence.
The term “recombinant” when used with reference, e.g., to a polypeptide, cell or nucleic acid, or vector, indicates that the polypeptide, cell, nucleic acid or vector, has been modified by (i) the introduction of a heterologous polypeptide, nucleic acid or protein, or (ii) the alteration of a native polypeptide, nucleic acid or protein, or (iii) that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all. Transgenic cells and plants are those that express a heterologous gene or coding sequence, typically as a result of recombinant methods.
The term “heterologous” when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein indicates that the protein comprises two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).
The terms “inhibitor,” “repressor” or “antagonist” or “downregulator” interchangeably refer to a substance that results in a detectably lower expression or activity level as compared to a control. The inhibited expression or activity can be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or less than that in a control. In certain instances, the inhibition is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more in comparison to a control.
A “control” sample or value refers to a sample that serves as a reference, usually a known reference, for comparison to a test sample. For example, a test sample can be taken from a test condition, e.g., in the presence of a test compound, and compared to samples from known conditions, e.g., in the absence of the test compound (negative control), or in the presence of a known compound (positive control). A control can also represent an average value gathered from a number of tests or results. One of skill in the art will recognize that controls can be designed for assessment of any number of parameters. For example, a control can be devised to compare therapeutic benefit based on pharmacological data (e.g., half-life) or therapeutic measures (e.g., comparison of benefit and/or side effects). Controls can be designed for in vitro applications. One of skill in the art will understand which controls are valuable in a given situation and be able to analyze data based on comparisons to control values. Controls are also valuable for determining the significance of data. For example, if values for a given parameter are widely variant in controls, variation in test samples will not be considered as significant.
A “label” or a “detectable moiety” is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means. For example, useful labels include 32P, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins or other entities which can be made detectable, e.g., by incorporating a radiolabel into a peptide or antibody specifically reactive with a target peptide. Any method known in the art for conjugating an antibody to the label may be employed, e.g., using methods described in Hermanson, Bioconjugate Techniques 1996, Academic Press, Inc., San Diego.
A “labeled” molecule (e.g., nucleic acid, protein, or antibody) is one that is bound, either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds to a label such that the presence of the molecule may be detected by detecting the presence of the label bound to the molecule.
The term “diagnosis” refers to a relative probability that a disorder such as infection or an inflammatory condition is present in the subject. Similarly, the term “prognosis” refers to a relative probability that a certain future outcome may occur in the subject. For example, prognosis can refer to the likelihood that an individual will develop a Bordetella infection, have recurrence, or the likely severity of the infection (e.g., severity of symptoms, rate of functional decline, survival, etc.). The terms are not intended to be absolute, as will be appreciated by any one of skill in the field of medical diagnostics.
A “biological sample” can be obtained from a patient, e.g., a biopsy, from an animal, such as an animal model, or from cultured cells, e.g., a cell line or cells removed from a patient and grown in culture for observation. Biological samples include tissues and bodily fluids, e.g., blood, blood fractions, lymph, saliva, sputum, mucus, urine, feces, etc.
The terms “therapy,” “treatment,” and “amelioration” refer to any reduction in the severity of symptoms or duration of infection. As used herein, the terms “treat” and “prevent” are not intended to be absolute terms. Treatment and prevention can refer to any delay in onset of symptoms, amelioration of symptoms, reduced duration of infection or symptoms, etc. Treatment and prevention can be complete (no detectable symptoms remaining) or partial, such that symptoms are less frequent of severe than in a patient without the treatment described herein. The effect of treatment can be compared to an individual or pool of individuals not receiving the treatment, or to the same patient prior to treatment or at a different time during treatment. In some aspects, the severity of infection or symptoms is reduced by at least 10%, as compared, e.g., to the individual before administration or to a control individual not undergoing treatment. In some aspects the severity of infection or symptoms is reduced by at least 25%, 50%, 75%, 80%, or 90%, or in some cases, no longer detectable using standard diagnostic techniques.
The terms “effective amount,” “effective dose,” “therapeutically effective amount,” etc. refer to that amount of the therapeutic agent sufficient to ameliorate a disorder, as described above. For example, for the given parameter, a therapeutically effective amount will show an increase or decrease of therapeutic effect at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100%. Therapeutic efficacy can also be expressed as “-fold” increase or decrease. For example, a therapeutically effective amount can have at least a 1.2-fold, 1.5-fold, 2-fold, 5-fold, or more effect over a control.
As used herein, the term “pharmaceutically acceptable” is used synonymously with physiologically acceptable and pharmacologically acceptable. A pharmaceutical composition will generally comprise agents for buffering and preservation in storage, and can include buffers and carriers for appropriate delivery, depending on the route of administration.
The terms “dose” and “dosage” are used interchangeably herein. A dose refers to the amount of active ingredient given to an individual at each administration. For the present invention, the dose can refer to the concentration of the antibody and/or associated components (e.g., excipients). The dose will vary depending on a number of factors, including frequency of administration; size and tolerance of the individual; severity of the infection; risk of side effects; and the route of administration. One of skill in the art will recognize that the dose can be modified depending on the above factors or based on therapeutic progress. The term “dosage form” refers to the particular format of the pharmaceutical, and depends on the route of administration. For example, a dosage form can be in a liquid, e.g., a saline solution for injection.
“Subject,” “patient,” “individual” and like terms are used interchangeably and refer to, except where indicated, mammals such as humans and non-human primates, as well as rabbits, rats, mice, goats, pigs, and other mammalian species. The term does not necessarily indicate that the subject has been diagnosed with a particular disease, but typically refers to an individual under medical supervision. A patient can be an individual that is seeking treatment, monitoring, adjustment or modification of an existing therapeutic regimen, etc.
Provided herein are neutralizing antibodies that bind to Bordetella ACT, in particular the RTX domain. A neutralizing antibody can inhibit or block is the ability of the ACT protein to enter a cell, increase cAMP levels, and/or bind αMβ2 integrin. In embodiments, the antibody binds with a Kd of less than about 100 nM, e.g., 0.01-100 nM, 0.1-20 nM, 0.5-10 nM. In embodiments, the antibody is humanized. The antibody can be of any isotype, e.g., IgG (IgG1, IgG2, IgG3, IgG4), IgM, IgA (IgA1, IgA2), IgD, and IgE isotype. In embodiments, the antibody is an antibody fragment (e.g., Fab, Fab′, F(ab)2, scAb).
A. Antibody Fragments
Antibodies as provided herein may be Fab, Fab′, or F(ab)2′ fragments. Where the antibodies are Fab, Fab′, or F(ab)2′ fragments, the antibodies include a heavy chain (e.g. including a partial constant and a variable region) and a light chain (e.g. including a constant and a variable region). In embodiments, the antibody is a humanized Fab, Fab′, or F(ab)2′ fragment.
In embodiments, the humanized antibody is a single chain antibody (scAb or scFv). A single chain antibody includes a variable light chain and a variable heavy chain. That is, a single chain antibody includes a single light chain and a single heavy chain, in contrast to an immunoglobulin (Ig) antibody, which includes two identical pairs of polypeptide chains, each pair having one light chain and one heavy chain. Each light chain and heavy chain (whether in an Ig or scAb) includes two regions: a variable (“V”) region (i.e. variable light chain and variable heavy chain) involved in binding the target antigen, and a constant (“C”) region that interacts with other components of the immune system. The variable light chain and the variable heavy chain in a single chain antibody can be linked through a linker peptide. Examples for linker peptides of single chain antibodies are described in Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S. M., Lee, T., Pope, S. H., Riordan, G. S, and Whitlow, M. (1988).
Methods of making scFv antibodies have been described. See, Huse et al., Science 246:1275-1281 (1989); Ward et al., Nature 341:544-546 (1989); and Vaughan et al., Nature Biotech. 14:309-314 (1996). For example, mRNA from B-cells from an immunized animal can be isolated and cDNA is prepared. The cDNA is amplified using primers specific for the variable regions of heavy and light chains of immunoglobulins. The PCR products are purified and the nucleic acid sequences are joined. If a linker peptide is desired, nucleic acid sequences that encode the peptide are inserted between the heavy and light chain nucleic acid sequences. The nucleic acid which encodes the scFv is inserted into a vector and expressed in the appropriate host cell.
B. Competitive Antibodies
In embodiments, the antibodies described herein compete with an antibody that is capable of binding Bordetella ACT, or a fragment thereof (e.g., comprising an immunogenic and soluble fragment of ACT, e.g., from the RTX domain). Where the antibody competes with an antibody (competitor antibody) for binding a target antigen, the antibody inhibits (completely or partially) binding of the competitor antibody to a measurable extent, e.g., binding of the competitor antibody to the antigen is reduced by at least 30%, usually at least about 40%, 50%, 60% or 75%, and often by at least about 90%, 95%, or more. Binding can be measured by any of the methods described herein.
In embodiments, the humanized antibody is an antibody which competes with an antibody that is capable of binding the RTX domain of Bordetella ACT. Thus, in embodiments, antibodies are provided that compete for binding to ACT with an antibody comprising sequences selected from the group consisting of: light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:1 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:2; light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:3 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:4; light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:5 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:6; light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:7 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:9; light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:9 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:10; and light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:11 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:12. In embodiments, antibodies are provided that compete for binding to ACT with an antibody comprising sequences selected from the group consisting of: light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:13 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:14; light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:15 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:16; light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:17 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:18. In embodiments, the antibody inhibits (completely or partially) ACT activity, e.g., by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%. In some further embodiments, the antibody does not compete for binding with an antibody selected from 3D1, 2A12, 10A1.
C. Humanized Antibodies
A humanized antibody is a genetically engineered antibody in which at least one CDR (or functional fragment thereof) from a mouse antibody (“donor antibody”, which can also be rat, hamster or other non-human species) are grafted onto a human antibody (“acceptor antibody”). In embodiments, more than one mouse CDR is grafted (e.g. all six mouse CDRs are grafted). The sequence of the acceptor antibody can be, for example, a mature human antibody sequence (or fragment thereof), a consensus sequence of a human antibody sequence (or fragment thereof), or a germline region sequence (or fragment thereof). Thus, a humanized antibody may be an antibody having one or more CDRs from a donor antibody and variable region framework (FR). The FR may form part of a constant region within a human antibody. In addition, in order to retain high binding affinity, amino acids in the human acceptor sequence may be replaced by the corresponding amino acids from the donor sequence, for example where: (1) the amino acid is in a CDR; (2) the amino acid is in the human framework region (e.g. the amino acid is immediately adjacent to one of the CDR's) (see, e.g., U.S. Pat. Nos. 5,530,101 and 5,585,089). Although humanized antibodies often incorporate all six CDRs (e.g. as defined by Kabat, Chothia, IMTG, etc.) from a mouse antibody, they can also be made with fewer mouse CDRs and/or less than the complete mouse CDR sequence (e.g. a functional fragment of a CDR). Thus, in embodiments only part of the donor CDRs, namely the subset of CDR residues required for binding, termed the SDRs, is incorporated into the humanized antibody.
Typically a humanized antibody can include (i) a light chain comprising at least one CDR (often three CDRs) from a mouse antibody (also referred to herein as a mouse CDR) and a human variable region framework; and (ii) a heavy chain comprising at least one CDR (often three CDRs) from the mouse antibody and a human variable region framework (FR). The light and heavy chain variable region frameworks (FRs) may each be a mature human antibody variable region framework sequence (or fragment thereof), a germline variable region framework sequence (combined with a J region sequence) (or fragment thereof), or a consensus sequence of a human antibody variable region framework sequence (or fragment thereof). In embodiments, the humanized antibody includes a light chain as described in (i), a heavy chain as described in (ii) together with a light chain human constant region and a heavy chain constant region.
In embodiments, the humanized antibody includes a human constant region. In embodiments, the humanized antibody is selected from an IgG (including IgG1, IgG2, IgG3, IgG4), IgM, IgA (IgA1, IgA2), IgD, and IgE isotype.
A chimeric antibody is an antibody in which the variable region of a mouse (or other rodent) antibody is combined with the constant region of a human antibody; their construction by means of genetic engineering is well-known. Such antibodies retain the binding specificity of the mouse antibody, while being about two-thirds human. The proportion of nonhuman sequence present in mouse, chimeric and humanized antibodies suggests that the immunogenicity of chimeric antibodies is intermediate between mouse and humanized antibodies. Other types of genetically engineered antibodies that may have reduced immunogenicity relative to mouse antibodies include human antibodies made using phage display methods (Dower et al., WO91/17271; McCafferty et al., WO92/001047; Winter, WO92/20791; and Winter, FEBS Lett. 23:92, 1998, each of which is incorporated herein by reference) or using transgenic animals (Lonberg et al., WO93/12227; Kucherlapati WO91/10741, each of which is incorporated herein by reference).
Other approaches to design humanized antibodies may also be used to achieve the same result as the methods in U.S. Pat. Nos. 5,530,101 and 5,585,089 described above, for example, “super-humanization” (see Tan et al. J. Immunol. 169: 1119, 2002, and U.S. Pat. No. 6,881,557).
In embodiments, an antibody as described herein includes a humanized heavy chain and a humanized light chain. As described above the variable regions of the heavy chain and the light chain of an antibody include complementarity determining regions (CDRs). CDRs are defined as regions within an antibody that are directly involved in antigen binding. Proceeding from the amino-terminus, these regions are designated CDR H1, CDR H2 and CDR H3 for the heavy chain, and CDR L1, CDR L2, and CDR L3 for the light chain, respectively. The CDRs are held in place by more conserved framework regions (FRs). Proceeding from the amino-terminus, these regions are designated FR H1, FR H2, FR H3, and FR H4 for the heavy chain and FR L1, FR L2, FR L3, and FR L4, for the light chain, respectively. For humanized antibodies, one or more of the CDRs are derived from a donor antibody (also referred to herein as a donor CDR, such as a mouse CDR), whereas the FRs are of human origin. The locations of CDR and FR regions and the numbering system can be defined by any system known in the art, e.g., Kabat, Chothia, or IMGT (see, e.g., the website at bioinforg.uk/abs or Lefranc et al. (2009) Nucl. Acids Res. 26:D1006). The numbering and CDRs shown in
D. Antibody Binding Assays
The specificity and affinity of the binding can be defined in terms of the comparative dissociation constants (Kd) of an for a target antigen, as compared to the dissociation constant with respect to the antibody and other materials in the environment or unrelated molecules in general. Typically, the Kd for the antibody with respect to the unrelated material will be at least 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, 200-fold or higher than Kd with respect to the target.
An antibody will typically bind with a Kd of less than about 1000 nM, e.g., less than 250, 100, 50, 20 or lower nM. In embodiments, the Kd of the antibody is less than 15, 10, 5, or 1 nM. In embodiments, the Kd is 1-100 nM, 0.1-50 nM, 0.1-10 nM, or 1-20 nM. The value of the dissociation constant (Kd) can be determined by well-known methods, and can be computed even for complex mixtures by methods as disclosed, e.g., in Caceci et al., Byte (1984) 9:340-362.
Affinity of an antibody for a target antigen can be determined according to methods known in the art, e.g., as reviewed in Ernst et al. Determination of Equilibrium Dissociation Constants, Therapeutic Monoclonal Antibodies (Wiley & Sons ed. 2009).
Quantitative ELISA, and similar array-based affinity methods can be used. ELISA (Enzyme linked immunosorbent signaling assay) is an antibody-based method. In some cases, an antibody specific for target of interest is affixed to a substrate, and contacted with a sample suspected of containing the target. The surface is then washed to remove unbound substances. Target binding can be detected in a variety of ways, e.g., using a second step with a labeled antibody, direct labeling of the target, or labeling of the primary antibody with a label that is detectable upon antigen binding. In some cases, the antigen is affixed to the substrate (e.g., using a substrate with high affinity for proteins, or a Strepavidin-biotin interaction) and detected using a labeled antibody (or other targeting moiety). Several permutations of the original ELISA methods have been developed and are known in the art (see Lequin (2005) Clin. Chem. 51:2415-18 for a review).
The Kd, Kon, and Koff can also be determined using surface plasmon resonance (SPR), e.g., as measured by using a Biacore T100 system. SPR techniques are reviewed, e.g., in Hahnfeld et al. Determination of Kinetic Data Using SPR Biosensors, Molecular Diagnosis of Infectious Diseases (2004). In a typical SPR experiment, one interactant (target or targeting agent) is immobilized on an SPR-active, gold-coated glass slide in a flow cell, and a sample containing the other interactant is introduced to flow across the surface. When light of a given frequency is shined on the surface, the changes to the optical reflectivity of the gold indicate binding, and the kinetics of binding.
Binding affinity can also be determined by anchoring a biotinylated interactant to a streptavidin (SA) sensor chip. The other interactant is then contacted with the chip and detected, e.g., as described in Abdessamad et al. (2002) Nuc. Acids Res. 30:e45.
The ability of a particular antibody to recognize the same epitope as another antibody can be determined by the ability of one antibody to competitively inhibit binding of a second antibody to an antigen, e.g., Bordetella ACT or a fragment thereof. Any of a number of competitive binding assays can be used to measure competition between two antibodies to the same antigen. An exemplary assay is a Biacore assay. Briefly, in these assays, binding sites can be mapped in structural terms by testing the ability of interactants, e.g. different antibodies, to inhibit the binding of another. Two consecutive antibody samples are injected in sufficient concentration to determine if the antibodies compete for binding of the same binding epitope.
Antibodies can be differentiated by the epitope to which they bind using a sandwich ELISA assay. This is carried out by using a capture antibody (e.g., such as an antibody listed in Table 2 or
For preparation of the presently described antibodies, e.g., recombinant or monoclonal antibodies, techniques known in the art can be used (see, e.g., Kohler & Milstein, Nature 256:495-497 (1975); Kozbor et al., Immunology Today 4: 72 (1983); Cole et al., pp. 77-96 in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. (1985); Coligan, Current Protocols in Immunology (1991); Harlow & Lane, Antibodies, A Laboratory Manual (1988); and Goding, Monoclonal Antibodies: Principles and Practice (2d ed. 1986)). The genes encoding the heavy and light chains of an antibody of interest can be cloned from a cell or phage display library, e.g., the genes encoding a monoclonal antibody can be cloned from a hybridoma or library and used to produce a recombinant monoclonal antibody. Gene libraries encoding heavy and light chains of monoclonal antibodies can also be made from hybridoma or plasma cells. Random combinations of the heavy and light chain gene products generate a large pool of antibodies with different antigenic specificity (see, e.g., Kuby, Immunology (3.sup.rd ed. 1997)). Techniques for the production of single chain antibodies or recombinant antibodies (U.S. Pat. No. 4,946,778, U.S. Pat. No. 4,816,567) can be adapted to produce the presently described antibodies. Also, transgenic mice, or other organisms such as other mammals, can be used to express humanized or human antibodies (see, e.g., U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, Marks et al., Bio/Technology 10:779-783 (1992); Lonberg et al., Nature 368:856-859 (1994); Morrison, Nature 368:812-13 (1994); Fishwild et al., Nature Biotechnology 14:845-51 (1996); Neuberger, Nature Biotechnology 14:826 (1996); and Lonberg & Huszar, Intern. Rev. Immunol. 13:65-93 (1995)). Alternatively, phage display technology can be used to identify antibodies and heteromeric Fab fragments that specifically bind to selected antigens (see, e.g., McCafferty et al., Nature 348:552-554 (1990); Marks et al., Biotechnology 10:779-783 (1992)). Any of the presently disclosed antibodies can also be included in a bispecific antibody that isable to recognize two different antigens (see, e.g., WO 93/08829, Traunecker et al., EMBO J. 10:3655-3659 (1991); and Suresh et al., Methods in Enzymology 121:210 (1986)). Antibodies can also be heteroconjugates, e.g., two covalently joined antibodies, or immunotoxins (see, e.g., U.S. Pat. No. 4,676,980, WO 91/00360; WO 92/200373; and EP 03089).
Antibodies can be produced using any number of expression systems, including prokaryotic and eukaryotic expression systems. In embodiments, the expression system is a mammalian cell expression, such as a hybridoma, or a CHO cell expression system. Many such systems are widely available from commercial suppliers. In embodiments in which an antibody comprises both a VH and VL region, the VH and VL regions may be expressed using a single vector, e.g., in a di-cistronic expression unit, or under the control of different promoters. In other embodiments, the VH and VL region may be expressed using separate vectors. A VH and VL region as described herein may optionally comprise a methionine at the N-terminus.
As noted above, the antibody can be produced in various formats, including as a Fab, a Fab′, a F(ab′)2, a scFv, or a dAB. The antibody fragments can be obtained by a variety of methods, including, digestion of an intact antibody with an enzyme, such as pepsin (to generate (Fab′)2 fragments) or papain (to generate Fab fragments); or de novo synthesis. Antibody fragments can also be synthesized using recombinant DNA methodology. An antibody of the invention can also include a human constant region. See, e.g., Fundamental Immunology (Paul ed., 4d ed. 1999); Bird, et al., Science 242:423 (1988); and Huston, et al., Proc. Natl. Acad. Sci. USA 85:5879 (1988).
In some cases, the antibody or antibody fragment can be conjugated to another molecule, e.g., polyethylene glycol (PEGylation) or serum albumin, to provide an extended half-life in vivo. Examples of PEGylation of antibody fragments are provided in Knight et al. Platelets 15:409, 2004 (for abciximab); Pedley et al., Br. J. Cancer 70:1126, 1994 (for an anti-CEA antibody); Chapman et al., Nature Biotech. 17:780, 1999; and Humphreys, et al., Protein Eng. Des. 20: 227, 2007).
Techniques for conjugating detectable agents to antibodies are well known (see, e.g., Amon et al., “Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy”, in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Thorpe, “Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review” in Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985); and Thorpe et al., “The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates”, Immunol. Rev., 62:119-58 (1982)).
For labeled antibodies, the label can include optical agents such as fluorescent agents, phosphorescent agents, chemiluminescent agents, and the like. Numerous agents (e.g., dyes, probes, labels, or indicators) are known in the art and can be used in the present invention. (See, e.g., Invitrogen, The Handbook—A Guide to Fluorescent Probes and Labeling Technologies, Tenth Edition (2005)). Fluorescent agents can include a variety of organic and/or inorganic small molecules or a variety of fluorescent proteins and derivatives thereof. For example, fluorescent agents can include but are not limited to cyanines, phthalocyanines, porphyrins, indocyanines, rhodamines, phenoxazines, phenylxanthenes, phenothiazines, phenoselenazines, fluoresceins, benzoporphyrins, squaraines, dipyrrolo pyrimidones, tetracenes, quinolines, pyrazines, corrins, croconiums, acridones, phenanthridines, rhodamines, acridines, anthraquinones, chalcogenopyrylium analogues, chlorins, naphthalocyanines, methine dyes, indolenium dyes, azo compounds, azulenes, azaazulenes, triphenyl methane dyes, indoles, benzoindoles, indocarbocyanines, benzoindocarbocyanines, and BODIPY derivatives. Fluorescent dyes are discussed, for example, in U.S. Pat. No. 4,452,720, U.S. Pat. No. 5,227,487, and U.S. Pat. No. 5,543,295.
Any of the presently disclosed antibodies can be used for in vitro diagnostic or monitoring methods, e.g., using cells or tissue from a patient sample. A labeled antibody can also be provided to an individual in vivo to determine the applicability of an intended therapy. For example, a labeled antibody may be used to detect the severity of bacterial infection in an affected area.
Effective neutralization, e.g., for treatment, generally relies on an appropriately high affinity, based on a slow kinetic off-rate. If a given antibody off-rate is slower than the clearance time of the antibody-toxin complex in human sera, then the antibody can effectively remove toxin stoichiometrically. Even if clearance rates are slower than antibody off-rates, higher affinity antibodies will be better able to neutralize smaller amounts of a toxin. Thus, high affinity antibodies can be used at much lower doses, reducing the chance for side effects such as unwanted immune reactions to the antibody therapeutic reagent. Antibodies with dissociation constants (Kd) of about 70 nM or lower are generally used therapeutically.
One of skill will appreciate that the nature of the pharmaceutical composition and route of administration will depend in part on the condition being treated.
Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the packaged nucleic acid suspended in diluents, such as water, saline or PEG 400; (b) capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as liquids, solids, granules or gelatin; (c) suspensions in an appropriate liquid; and (d) suitable emulsions. Tablet forms can include one or more of lactose, sucrose, mannitol, sorbitol, calcium phosphates, corn starch, potato starch, microcrystalline cellulose, gelatin, colloidal silicon dioxide, talc, magnesium stearate, stearic acid, and other excipients, colorants, fillers, binders, diluents, buffering agents, moistening agents, preservatives, flavoring agents, dyes, disintegrating agents, and pharmaceutically compatible carriers. Lozenge forms can comprise the active ingredient in a flavor, e.g., sucrose, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the active ingredient, carriers known in the art.
A pharmaceutical composition comprising an antibody described herein can be administered, alone or in combination with other suitable components, can be made into aerosol formulations (“nebulized”) to be administered via inhalation. Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, etc.
Suitable formulations for rectal administration include, for example, suppositories, which consist of the packaged nucleic acid with a suppository base. Suitable suppository bases include natural or synthetic triglycerides or paraffin hydrocarbons. In addition, it is also possible to use gelatin rectal capsules which consist of a combination of the compound of choice with a base, including, for example, liquid triglycerides, polyethylene glycols, and paraffin hydrocarbons.
Formulations suitable for parenteral administration, such as, for example, by intraarticular (in the joints), intravenous, intramuscular, intratumoral, intradermal, intraperitoneal, and subcutaneous routes, include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. In the practice of this invention, compositions can be administered, for example, by intravenous infusion, orally, topically, intraperitoneally, intravesically or intrathecally. Antibodies are typically administered by parenteral or intravenous administration. The formulations of compounds can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials.
Injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described. Methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art and are described in more detail in such publications as Remington's Pharmaceutical Science, 15th ed., Mack Publishing Company, Easton, Pa. (1980).
The compositions for administration typically comprises an antibody as described herein (a neutralizing anti-ACT antibody) dissolved in a pharmaceutically acceptable carrier, e.g., an aqueous carrier. A variety of aqueous carriers can be used, e.g., buffered saline. These solutions are sterile and generally free of undesirable matter. These compositions may be sterilized by conventional, well known sterilization techniques. The compositions can contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, etc. The concentration of active agent in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the patient's needs.
The formulation may also provide additional active compounds, including, e.g., antibacterial agents. The active ingredients can be prepared as sustained-release preparations (e.g., semi-permeable matrices of solid hydrophobic polymers (e.g., polyesters, hydrogels (for example, poly (2-hydroxyethyl-methacrylate), poly-vinylalcohol, polylactides). Antibodies and associated compounds can also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin microcapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions.
The compositions can be administered for therapeutic or prophylactic treatments. In therapeutic applications, compositions are administered to a patient exposed to Bordetella in a “therapeutically effective dose.” Amounts effective for this use will depend upon the disorder to be treated, the route of administration, the severity of the condition, and the general state of the patient's health. Single or multiple administrations of the compositions may be administered depending on the dosage and frequency as required and tolerated by the patient. The presently described compositions can be administered to humans and other animals, particularly mammals. Thus the methods are applicable to both human therapy and veterinary applications. Other known cancer therapies can be used in combination with the methods of the invention. For example, the compositions for use as described herein can also be used to increase a patient's immune response to Bordetella.
Combination therapies contemplate coadministration, using separate formulations or a single pharmaceutical formulation, and consecutive administration in either order.
To determine a therapeutically effective dose, a low dose of an anti-Bordetella antibody can be initially administered to the individual, and the dose can be incrementally increased until the condition of the individual begins to improve. For example, the initial dosage can be about 0.001 mg/kg to about 1 mg/kg daily. A daily dose range of about 0.01 mg/kg to about 500 mg/kg, or about 0.1 mg/kg to about 200 mg/kg, or about 1 mg/kg to about 100 mg/kg, or about 10 mg/kg to about 50 mg/kg, can be used at later time points if the condition of the individual does not change at the lowest dose. As noted above, one of skill will appreciate that a number of variables must be considered when determining a therapeutically effective dose. The dose administered to a patient should be sufficient to effect a beneficial therapeutic response in the patient over time. The size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects that accompany the administration of a particular composition (or combination therapy) in a particular patient.
It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, patent applications, and public database entries cited herein are hereby incorporated by reference in their entireties for all purposes.
“Bordetella adenylate cyclase toxin protein” or “Bordetella ACT protein” is used according to its common, ordinary meaning and refers to proteins of the same or similar names and functional fragments and homologs thereof. The term includes recombinant or naturally occurring forms of Bordetella ACT protein (e.g., UniProt accession number C8C508; SEQ ID NO:28), or variants thereof that maintain Bordetella ACT protein activity (e.g. within at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 100% as compared to SEQ ID NO:28). The term includes recombinant or naturally occurring forms of Bordetella ACT protein or variants thereof that have sequence identity to SEQ ID NO:28 (e.g., about 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NO:28). Bordetella ACT protein may refer to variants having mutated amino acid residues that modulate (e.g. increase or decrease when compared to Bordetella ACT protein) Bordetella ACT protein activity, expression, cellular targeting, or protein translocation. As provided herein Bordetella ACT protein includes, without limitation, ACT proteins of Bordetella pertussis, Bordetella bronchioseptica, Bordetella ansorpii, Bordetella avium, Bordetella hinzii, Bordetella holmesii, Bordetellapetrii, Bordetella trematum or Bordetella parapertussis. Thus, in embodiments, the Bordetella adenylate cyclase toxin protein has the sequence of SEQ ID NO:28, SEQ ID NO:29 or SEQ ID NO:30.
The terms “αMβ2 integrin” or “CD11B” as referred to herein include any of the recombinant or naturally-occurring forms of the Cluster of Differentiation 11B (CD11B) also known as Integrin alpha M (ITGAM), heterodimeric integrin alpha-M beta-2 (αMβ2) molecule, macrophage-1 antigen (Mac-1) or complement receptor 3 (CR3), or variants or homologs thereof that maintain CD11B activity (e.g., within at least 50%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% activity compared to CD11B). In some aspects, the variants or homologs have at least 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity across the whole sequence or a portion of the sequence (e.g. a 50, 100, 150 or 200 continuous amino acid portion) compared to a naturally occurring CD11B protein. In embodiments, the CD11B protein is substantially identical to the protein identified by the UniProt reference number P11215 or a variant or homolog having substantial identity thereto. In embodiments, the CD11B protein is substantially identical to the protein identified by the UniProt reference number P05555 or a variant or homolog having substantial identity thereto.
The terms “numbered with reference to” or “corresponding to,” when used in the context of the numbering of a given amino acid or polynucleotide sequence, refers to the numbering of the residues of a specified reference sequence when the given amino acid or polynucleotide sequence is compared to a reference sequence. In embodiments, the reference sequence is the sequence of amino acid residue 700-1076 of Bordetella adenylate cyclase toxin protein. In embodiments, the reference sequence is SEQ ID NO:28. In embodiments, the reference sequence is SEQ ID NO:29. In embodiments, the reference sequence is SEQ ID NO:30. In embodiments, the comparison to the reference sequence is a sequence alignment between the given amino acid or polynucleotide sequence and the reference sequence.
The sequence of the recombinant Bordetella adenylate cyclase toxin polypeptide as described herein corresponds to residues corresponding to positions 700-1706 of the Bordetella adenylate cyclase toxin protein or an immunogenic fragment thereof. One skilled in the art will immediately recognize the identity and location of residues corresponding to positions 700-1706 of the Bordetella adenylate cyclase toxin protein in other Bordetella adenylate cyclase toxin proteins with different numbering systems. For example, by performing a simple sequence alignment with Bordetella adenylate cyclase toxin protein the identity and location of residues corresponding to positions 700-1706 of the Bordetella adenylate cyclase toxin protein are identified in other Bordetella adenylate cyclase toxin proteins (e.g., Bordetella pertussis, Bordetella bronchioseptica or Bordetella parapertussis).
In one aspect a vaccine composition is provided. The composition includes a recombinant Bordetella adenylate cyclase toxin polypeptide consisting essentially of a sequence corresponding to amino acid residues 700-1706 of Bordetella adenylate cyclase toxin protein or an immunogenic fragment thereof and a pharmaceutically acceptable vaccine excipient. The recombinant Bordetella adenylate cyclase toxin polypeptide or immunogenic fragment thereof provided herein are immunogenic polypeptides that upon administration to a human patient or animal generate antibodies that specifically bind to the Bordetella adenylate cyclase toxin protein. An immunogenic peptide is capable of inducing an immunological response against itself upon administration to a mammal, optionally in conjunction with an adjuvant.
The term “consisting essentially of” in this context refers to a recombinant Bordetella adenylate cyclase toxin polypeptide including a sequence corresponding to amino acid residues 700-1706 of Bordetella adenylate cyclase toxin protein or an immunogenic fragment thereof and no other sequence that is independently capable of generating antibodies that specifically bind to the Bordetella adenylate cyclase toxin protein or a portion of the Bordetella adenylate cyclase toxin protein.
In embodiments, the recombinant Bordetella adenylate cyclase toxin polypeptide consists of a sequence corresponding to amino acid residues 700-1706 of Bordetella adenylate cyclase toxin protein or an immunogenic fragment thereof and a pharmaceutically acceptable vaccine excipient. Where the Bordetella adenylate cyclase toxin polypeptide consists of a sequence corresponding to amino acid residues 700-1706 of Bordetella adenylate cyclase toxin protein or an immunogenic fragment thereof, the recombinant polypeptide includes a sequence corresponding to amino acid residues 700-1706 of Bordetella adenylate cyclase toxin protein or an immunogenic fragment thereof and no other sequence. Thus, in embodiments, the sequence corresponds to amino acid residues 700-1706. In embodiments, the sequence corresponds to amino acid residues 705-1706. In embodiments, the sequence corresponds to amino acid residues 710-1706. In embodiments, the sequence corresponds to amino acid residues 715-1706. In embodiments, the sequence corresponds to amino acid residues 720-1706. In embodiments, the sequence corresponds to amino acid residues 725-1706. In embodiments, the sequence corresponds to amino acid residues 730-1706. In embodiments, the sequence corresponds to amino acid residues 735-1706. In embodiments, the sequence corresponds to amino acid residues 740-1706. In embodiments, the sequence corresponds to amino acid residues 745-1706. In embodiments, the sequence corresponds to amino acid residues 750-1706. In embodiments, the sequence corresponds to amino acid residues 751-1706. In embodiments, the sequence corresponds to amino acid residues 752-1706. In embodiments, the sequence corresponds to amino acid residues 753-1706. In embodiments, the sequence corresponds to amino acid residues 754-1706. In embodiments, the sequence corresponds to amino acid residues 755-1706. In embodiments, the sequence corresponds to amino acid residues 756-1706. In embodiments, the sequence corresponds to amino acid residues 757-1706. In embodiments, the sequence corresponds to amino acid residues 758-1706. In embodiments, the sequence corresponds to amino acid residues 759-1706. In embodiments, the sequence corresponds to amino acid residues 760-1706.
In embodiments, the sequence corresponds to amino acid residues 765-1706. In embodiments, the sequence corresponds to amino acid residues 770-1706. In embodiments, the sequence corresponds to amino acid residues 775-1706. In embodiments, the sequence corresponds to amino acid residues 780-1706. In embodiments, the sequence corresponds to amino acid residues 785-1706. In embodiments, the sequence corresponds to amino acid residues 790-1706. In embodiments, the sequence corresponds to amino acid residues 795-1706. In embodiments, the sequence corresponds to amino acid residues 800-1706. In embodiments, the sequence corresponds to amino acid residues 805-1706. In embodiments, the sequence corresponds to amino acid residues 810-1706. In embodiments, the sequence corresponds to amino acid residues 815-1706. In embodiments, the sequence corresponds to amino acid residues 820-1706. In embodiments, the sequence corresponds to amino acid residues 825-1706. In embodiments, the sequence corresponds to amino acid residues 830-1706. In embodiments, the sequence corresponds to amino acid residues 835-1706. In embodiments, the sequence corresponds to amino acid residues 840-1706. In embodiments, the sequence corresponds to amino acid residues 845-1706. In embodiments, the sequence corresponds to amino acid residues 850-1706. In embodiments, the sequence corresponds to amino acid residues 855-1706. In embodiments, the sequence corresponds to amino acid residues 860-1706. In embodiments, the sequence corresponds to amino acid residues 865-1706. In embodiments, the sequence corresponds to amino acid residues 870-1706. In embodiments, the sequence corresponds to amino acid residues 875-1706. In embodiments, the sequence corresponds to amino acid residues 880-1706. In embodiments, the sequence corresponds to amino acid residues 885-1706. In embodiments, the sequence corresponds to amino acid residues 890-1706. In embodiments, the sequence corresponds to amino acid residues 895-1706.
In embodiments, the sequence corresponds to amino acid residues 900-1706. In embodiments, the sequence corresponds to amino acid residues 910-1706. In embodiments, the sequence corresponds to amino acid residues 920-1706. In embodiments, the sequence corresponds to amino acid residues 930-1706. In embodiments, the sequence corresponds to amino acid residues 940-1706. In embodiments, the sequence corresponds to amino acid residues 950-1706. In embodiments, the sequence corresponds to amino acid residues 960-1706. In embodiments, the sequence corresponds to amino acid residues 970-1706. In embodiments, the sequence corresponds to amino acid residues 975-1706. In embodiments, the sequence corresponds to amino acid residues 980-1706. In embodiments, the sequence corresponds to amino acid residues 981-1706. In embodiments, the sequence corresponds to amino acid residues 982-1706. In embodiments, the sequence corresponds to amino acid residues 983-1706. In embodiments, the sequence corresponds to amino acid residues 984-1706. In embodiments, the sequence corresponds to amino acid residues 985-1706. In embodiments, the sequence corresponds to amino acid residues 986-1706. In embodiments, the sequence corresponds to amino acid residues 987-1706. In embodiments, the sequence corresponds to amino acid residues 988-1706. In embodiments, the sequence corresponds to amino acid residues 989-1706. In embodiments, the sequence corresponds to amino acid residues 990-1706. In embodiments, the sequence corresponds to amino acid residues 995-1706. In embodiments, the sequence corresponds to amino acid residues 996-1706. In embodiments, the sequence corresponds to amino acid residues 997-1706. In embodiments, the sequence corresponds to amino acid residues 998-1706. In embodiments, the sequence corresponds to amino acid residues 999-1706.
In embodiments, the sequence corresponds to amino acid residues 1000-1706. In embodiments, the sequence corresponds to amino acid residues 1001-1706. In embodiments, the sequence corresponds to amino acid residues 1002-1706. In embodiments, the sequence corresponds to amino acid residues 1003-1706. In embodiments, the sequence corresponds to amino acid residues 1004-1706. In embodiments, the sequence corresponds to amino acid residues 1005-1706. In embodiments, the sequence corresponds to amino acid residues 1006-1706. In embodiments, the sequence corresponds to amino acid residues 1007-1706. In embodiments, the sequence corresponds to amino acid residues 1008-1706. In embodiments, the sequence corresponds to amino acid residues 1009-1706. In embodiments, the sequence corresponds to amino acid residues 1010-1706. In embodiments, the sequence corresponds to amino acid residues 1020-1706. In embodiments, the sequence corresponds to amino acid residues 1030-1706. In embodiments, the sequence corresponds to amino acid residues 1040-1706. In embodiments, the sequence corresponds to amino acid residues 1050-1706. In embodiments, the sequence corresponds to amino acid residues 1060-1706. In embodiments, the sequence corresponds to amino acid residues 1070-1706. In embodiments, the sequence corresponds to amino acid residues 1080-1706. In embodiments, the sequence corresponds to amino acid residues 1090-1706. In embodiments, the sequence corresponds to amino acid residues 1091-1706. In embodiments, the sequence corresponds to amino acid residues 1092-1706. In embodiments, the sequence corresponds to amino acid residues 1093-1706. In embodiments, the sequence corresponds to amino acid residues 1094-1706. In embodiments, the sequence corresponds to amino acid residues 1095-1706. In embodiments, the sequence corresponds to amino acid residues 1096-1706. In embodiments, the sequence corresponds to amino acid residues 1097-1706. In embodiments, the sequence corresponds to amino acid residues 1098-1706. In embodiments, the sequence corresponds to amino acid residues 1099-1706. In embodiments, the sequence corresponds to amino acid residues 1100-1706.
In embodiments, the sequence corresponds to amino acid residues 700-1705. In embodiments, the sequence corresponds to amino acid residues 705-1705. In embodiments, the sequence corresponds to amino acid residues 710-1705. In embodiments, the sequence corresponds to amino acid residues 715-1705. In embodiments, the sequence corresponds to amino acid residues 720-1705. In embodiments, the sequence corresponds to amino acid residues 725-1705. In embodiments, the sequence corresponds to amino acid residues 730-1705. In embodiments, the sequence corresponds to amino acid residues 735-1705. In embodiments, the sequence corresponds to amino acid residues 740-1705. In embodiments, the sequence corresponds to amino acid residues 745-1705. In embodiments, the sequence corresponds to amino acid residues 750-1705. In embodiments, the sequence corresponds to amino acid residues 751-1705. In embodiments, the sequence corresponds to amino acid residues 752-1705. In embodiments, the sequence corresponds to amino acid residues 753-1705. In embodiments, the sequence corresponds to amino acid residues 754-1705. In embodiments, the sequence corresponds to amino acid residues 755-1705. In embodiments, the sequence corresponds to amino acid residues 756-1705. In embodiments, the sequence corresponds to amino acid residues 757-1705. In embodiments, the sequence corresponds to amino acid residues 758-1705. In embodiments, the sequence corresponds to amino acid residues 759-1705. In embodiments, the sequence corresponds to amino acid residues 760-1705.
In embodiments, the sequence corresponds to amino acid residues 765-1705. In embodiments, the sequence corresponds to amino acid residues 770-1705. In embodiments, the sequence corresponds to amino acid residues 775-1705. In embodiments, the sequence corresponds to amino acid residues 780-1705. In embodiments, the sequence corresponds to amino acid residues 785-1705. In embodiments, the sequence corresponds to amino acid residues 790-1705. In embodiments, the sequence corresponds to amino acid residues 795-1705. In embodiments, the sequence corresponds to amino acid residues 800-1705. In embodiments, the sequence corresponds to amino acid residues 805-1705. In embodiments, the sequence corresponds to amino acid residues 810-1705. In embodiments, the sequence corresponds to amino acid residues 815-1705. In embodiments, the sequence corresponds to amino acid residues 820-1705. In embodiments, the sequence corresponds to amino acid residues 825-1705. In embodiments, the sequence corresponds to amino acid residues 830-1705. In embodiments, the sequence corresponds to amino acid residues 835-1705. In embodiments, the sequence corresponds to amino acid residues 840-1705. In embodiments, the sequence corresponds to amino acid residues 845-1705. In embodiments, the sequence corresponds to amino acid residues 850-1705. In embodiments, the sequence corresponds to amino acid residues 855-1705. In embodiments, the sequence corresponds to amino acid residues 860-1705. In embodiments, the sequence corresponds to amino acid residues 865-1705. In embodiments, the sequence corresponds to amino acid residues 870-1705. In embodiments, the sequence corresponds to amino acid residues 875-1705. In embodiments, the sequence corresponds to amino acid residues 880-1705. In embodiments, the sequence corresponds to amino acid residues 885-1705. In embodiments, the sequence corresponds to amino acid residues 890-1705. In embodiments, the sequence corresponds to amino acid residues 895-1705.
In embodiments, the sequence corresponds to amino acid residues 900-1705. In embodiments, the sequence corresponds to amino acid residues 910-1705. In embodiments, the sequence corresponds to amino acid residues 920-1705. In embodiments, the sequence corresponds to amino acid residues 930-1705. In embodiments, the sequence corresponds to amino acid residues 940-1705. In embodiments, the sequence corresponds to amino acid residues 950-1705. In embodiments, the sequence corresponds to amino acid residues 960-1705. In embodiments, the sequence corresponds to amino acid residues 970-1705. In embodiments, the sequence corresponds to amino acid residues 975-1705. In embodiments, the sequence corresponds to amino acid residues 980-1705. In embodiments, the sequence corresponds to amino acid residues 981-1705. In embodiments, the sequence corresponds to amino acid residues 982-1705. In embodiments, the sequence corresponds to amino acid residues 983-1705. In embodiments, the sequence corresponds to amino acid residues 984-1705. In embodiments, the sequence corresponds to amino acid residues 985-1705. In embodiments, the sequence corresponds to amino acid residues 986-1705. In embodiments, the sequence corresponds to amino acid residues 987-1705. In embodiments, the sequence corresponds to amino acid residues 988-1705. In embodiments, the sequence corresponds to amino acid residues 989-1705. In embodiments, the sequence corresponds to amino acid residues 990-1705. In embodiments, the sequence corresponds to amino acid residues 995-1705. In embodiments, the sequence corresponds to amino acid residues 996-1705. In embodiments, the sequence corresponds to amino acid residues 997-1705. In embodiments, the sequence corresponds to amino acid residues 998-1705. In embodiments, the sequence corresponds to amino acid residues 999-1705.
In embodiments, the sequence corresponds to amino acid residues 1000-1705. In embodiments, the sequence corresponds to amino acid residues 1001-1705. In embodiments, the sequence corresponds to amino acid residues 1002-1705. In embodiments, the sequence corresponds to amino acid residues 1003-1705. In embodiments, the sequence corresponds to amino acid residues 1004-1705. In embodiments, the sequence corresponds to amino acid residues 1005-1705. In embodiments, the sequence corresponds to amino acid residues 1006-1705. In embodiments, the sequence corresponds to amino acid residues 1007-1705. In embodiments, the sequence corresponds to amino acid residues 1008-1705. In embodiments, the sequence corresponds to amino acid residues 1009-1705. In embodiments, the sequence corresponds to amino acid residues 1010-1705. In embodiments, the sequence corresponds to amino acid residues 1020-1705. In embodiments, the sequence corresponds to amino acid residues 1030-1705. In embodiments, the sequence corresponds to amino acid residues 1040-1705. In embodiments, the sequence corresponds to amino acid residues 1050-1705. In embodiments, the sequence corresponds to amino acid residues 1060-1705. In embodiments, the sequence corresponds to amino acid residues 1070-1705. In embodiments, the sequence corresponds to amino acid residues 1080-1705. In embodiments, the sequence corresponds to amino acid residues 1090-1705. In embodiments, the sequence corresponds to amino acid residues 1091-1705. In embodiments, the sequence corresponds to amino acid residues 1092-1705. In embodiments, the sequence corresponds to amino acid residues 1093-1705. In embodiments, the sequence corresponds to amino acid residues 1094-1705. In embodiments, the sequence corresponds to amino acid residues 1095-1705. In embodiments, the sequence corresponds to amino acid residues 1096-1705. In embodiments, the sequence corresponds to amino acid residues 1097-1705. In embodiments, the sequence corresponds to amino acid residues 1098-1705. In embodiments, the sequence corresponds to amino acid residues 1099-1705. In embodiments, the sequence corresponds to amino acid residues 1100-1705.
In embodiments, the sequence corresponds to amino acid residues 700-1600. In embodiments, the sequence corresponds to amino acid residues 705-1600. In embodiments, the sequence corresponds to amino acid residues 710-1600. In embodiments, the sequence corresponds to amino acid residues 715-1600. In embodiments, the sequence corresponds to amino acid residues 720-1600. In embodiments, the sequence corresponds to amino acid residues 725-1600. In embodiments, the sequence corresponds to amino acid residues 730-1600. In embodiments, the sequence corresponds to amino acid residues 735-1600. In embodiments, the sequence corresponds to amino acid residues 740-1600. In embodiments, the sequence corresponds to amino acid residues 745-1600. In embodiments, the sequence corresponds to amino acid residues 750-1600. In embodiments, the sequence corresponds to amino acid residues 751-1600. In embodiments, the sequence corresponds to amino acid residues 752-1600. In embodiments, the sequence corresponds to amino acid residues 753-1600. In embodiments, the sequence corresponds to amino acid residues 754-1600. In embodiments, the sequence corresponds to amino acid residues 755-1600. In embodiments, the sequence corresponds to amino acid residues 756-1600. In embodiments, the sequence corresponds to amino acid residues 757-1600. In embodiments, the sequence corresponds to amino acid residues 758-1600. In embodiments, the sequence corresponds to amino acid residues 759-1600. In embodiments, the sequence corresponds to amino acid residues 760-1600.
In embodiments, the sequence corresponds to amino acid residues 765-1600. In embodiments, the sequence corresponds to amino acid residues 770-1600. In embodiments, the sequence corresponds to amino acid residues 775-1600. In embodiments, the sequence corresponds to amino acid residues 780-1600. In embodiments, the sequence corresponds to amino acid residues 785-1600. In embodiments, the sequence corresponds to amino acid residues 790-1600. In embodiments, the sequence corresponds to amino acid residues 795-1600. In embodiments, the sequence corresponds to amino acid residues 800-1600. In embodiments, the sequence corresponds to amino acid residues 805-1600. In embodiments, the sequence corresponds to amino acid residues 810-1600. In embodiments, the sequence corresponds to amino acid residues 815-1600. In embodiments, the sequence corresponds to amino acid residues 820-1600. In embodiments, the sequence corresponds to amino acid residues 825-1600. In embodiments, the sequence corresponds to amino acid residues 830-1600. In embodiments, the sequence corresponds to amino acid residues 835-1600. In embodiments, the sequence corresponds to amino acid residues 840-1600. In embodiments, the sequence corresponds to amino acid residues 845-1600. In embodiments, the sequence corresponds to amino acid residues 850-1600. In embodiments, the sequence corresponds to amino acid residues 855-1600. In embodiments, the sequence corresponds to amino acid residues 860-1600. In embodiments, the sequence corresponds to amino acid residues 865-1600. In embodiments, the sequence corresponds to amino acid residues 870-1600. In embodiments, the sequence corresponds to amino acid residues 875-1600. In embodiments, the sequence corresponds to amino acid residues 880-1600. In embodiments, the sequence corresponds to amino acid residues 885-1600. In embodiments, the sequence corresponds to amino acid residues 890-1600. In embodiments, the sequence corresponds to amino acid residues 895-1600.
In embodiments, the sequence corresponds to amino acid residues 900-1600. In embodiments, the sequence corresponds to amino acid residues 910-1600. In embodiments, the sequence corresponds to amino acid residues 920-1600. In embodiments, the sequence corresponds to amino acid residues 930-1600. In embodiments, the sequence corresponds to amino acid residues 940-1600. In embodiments, the sequence corresponds to amino acid residues 950-1600. In embodiments, the sequence corresponds to amino acid residues 960-1600. In embodiments, the sequence corresponds to amino acid residues 970-1600. In embodiments, the sequence corresponds to amino acid residues 975-1600. In embodiments, the sequence corresponds to amino acid residues 980-1600. In embodiments, the sequence corresponds to amino acid residues 981-1600. In embodiments, the sequence corresponds to amino acid residues 982-1600. In embodiments, the sequence corresponds to amino acid residues 983-1600. In embodiments, the sequence corresponds to amino acid residues 984-1600. In embodiments, the sequence corresponds to amino acid residues 985-1600. In embodiments, the sequence corresponds to amino acid residues 986-1600. In embodiments, the sequence corresponds to amino acid residues 987-1600. In embodiments, the sequence corresponds to amino acid residues 988-1600. In embodiments, the sequence corresponds to amino acid residues 989-1600. In embodiments, the sequence corresponds to amino acid residues 990-1600. In embodiments, the sequence corresponds to amino acid residues 995-1600. In embodiments, the sequence corresponds to amino acid residues 996-1600. In embodiments, the sequence corresponds to amino acid residues 997-1600. In embodiments, the sequence corresponds to amino acid residues 998-1600. In embodiments, the sequence corresponds to amino acid residues 999-1600.
In embodiments, the sequence corresponds to amino acid residues 1000-1600. In embodiments, the sequence corresponds to amino acid residues 1001-1600. In embodiments, the sequence corresponds to amino acid residues 1002-1600. In embodiments, the sequence corresponds to amino acid residues 1003-1600. In embodiments, the sequence corresponds to amino acid residues 1004-1600. In embodiments, the sequence corresponds to amino acid residues 1005-1600. In embodiments, the sequence corresponds to amino acid residues 1006-1600. In embodiments, the sequence corresponds to amino acid residues 1007-1600. In embodiments, the sequence corresponds to amino acid residues 1008-1600. In embodiments, the sequence corresponds to amino acid residues 1009-1600. In embodiments, the sequence corresponds to amino acid residues 1010-1600. In embodiments, the sequence corresponds to amino acid residues 1020-1600. In embodiments, the sequence corresponds to amino acid residues 1030-1600. In embodiments, the sequence corresponds to amino acid residues 1040-1600. In embodiments, the sequence corresponds to amino acid residues 1050-1600. In embodiments, the sequence corresponds to amino acid residues 1060-1600. In embodiments, the sequence corresponds to amino acid residues 1070-1600. In embodiments, the sequence corresponds to amino acid residues 1080-1600. In embodiments, the sequence corresponds to amino acid residues 1090-1600. In embodiments, the sequence corresponds to amino acid residues 1091-1600. In embodiments, the sequence corresponds to amino acid residues 1092-1600. In embodiments, the sequence corresponds to amino acid residues 1093-1600. In embodiments, the sequence corresponds to amino acid residues 1094-1600. In embodiments, the sequence corresponds to amino acid residues 1095-1600. In embodiments, the sequence corresponds to amino acid residues 1096-1600. In embodiments, the sequence corresponds to amino acid residues 1097-1600. In embodiments, the sequence corresponds to amino acid residues 1098-1600. In embodiments, the sequence corresponds to amino acid residues 1099-1600. In embodiments, the sequence corresponds to amino acid residues 1100-1600.
As described herein the polypeptide provided herein may consist essentially of a sequence corresponding to amino acid residues 700-1706 of Bordetella adenylate cyclase toxin protein or an immunogenic fragment thereof. In embodiments, the sequence includes a detectable moiety. In embodiments, the detectable moiety is a peptide. In embodiments, the detectable moiety is a poly-histidine peptide. In embodiments, the sequence is SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37 or SEQ ID NO:38. In embodiments, the sequence is SEQ ID NO:31. In embodiments, the sequence is SEQ ID NO:32. In embodiments, the sequence is SEQ ID NO:33. In embodiments, the sequence is SEQ ID NO:34. In embodiments, the sequence is SEQ ID NO:35. In embodiments, the sequence is SEQ ID NO:36. In embodiments, the sequence is SEQ ID NO:37. In embodiments, the sequence is SEQ ID NO:38.
The sequences of the recombinant Bordetella adenylate cyclase toxin polypeptide provided herein may include an acylated amino acid residue. An “acylated amino acid residue” as provided herein refers to an amino acid covalently attached to an acyl group (R—C(O)—). Thus, in embodiments, the sequence includes an acylated amino acid residue. In embodiments, the sequence includes an acylated amino acid residue at a position corresponding to K983 or K860. In further embodiments, the Bordetella adenylate cyclase toxin polypeptide binds αMβ2 integrin. In embodiments, the sequence includes an acylated amino acid residue at a position corresponding to K860. In embodiments, the sequence includes an acylated amino acid residue at a position corresponding to K983. In embodiments, the acylated residue is a lysine.
In embodiments, the Bordetella adenylate cyclase toxin polypeptide binds αMβ2 integrin. In embodiment, where the Bordetella adenylate cyclase toxin polypeptide binds αMβ2 integrin, the polypeptide or immunogenic fragment thereof is internalized if bound to αMβ2 integrin expressed on a cell (e.g., a leukocyte involved in the innate immune system, including monocyte, granulocyte, macrophage, and natural killer cell). In embodiments, where the Bordetella adenylate cyclase toxin polypeptide binds αMβ2 integrin, the polypeptide or immunogenic fragment thereof is capable of competitively inhibiting the binding of a αMβ2 integrin antibody (i.e., an antibody that specifically binds αMβ2 integrin). Thus, the Bordetella adenylate cyclase toxin polypeptide that binds αMβ2 integrin may recognize the same epitope as a αMβ2 integrin antibody. Any of a number of competitive binding assays can be used to measure competition between the polypeptide and the antibody to the same antigen (αMβ2 integrin). An exemplary assay is a Biacore® assay. Briefly, in these assays, binding sites can be mapped in structural terms by testing the ability of interactants, e.g. different polypeptides to inhibit the binding of another. Other conventional immunoassays known in the art can be used in the present invention. For example, antibodies and polypeptides can be differentiated by the epitope to which they bind using a sandwich ELISA assay. This is carried out by using a capture antibody (e.g. a mouse αMβ2 integrin antibody) to coat the surface of a well. A sub-saturating concentration of tagged-antigen (αMβ2 integrin) is then added to the capture surface. This protein will be bound to the antibody through a specific antibody:epitope interaction. After washing a recombinant Bordetella adenylate cyclase toxin polypeptide as provided herein (e.g. a polypeptide capable of binding αMβ2 integrin), which has been covalently linked to a detectable moiety (e.g., HRP, polyhistidine (HIS-tag)) is added to the ELISA. If the polypeptide recognizes the same epitope as the capture antibody it will be unable to bind to the target protein as that particular epitope will no longer be available for binding and no signal will be detected. Alternatively, the αMβ2 integrin may be allowed to bind the Bordetella adenylate cyclase toxin polypeptide as provided herein, thereby forming a receptor-polypeptide complex and preventing subsequent interaction with a αMβ2 integrin specific antibody.
In embodiments, the Bordetella adenylate cyclase toxin polypeptide as provided herein competes with an antibody that is capable of binding αMβ2 integrin. In embodiments, where the Bordetella adenylate cyclase toxin polypeptide competes with an antibody (competitor antibody) for binding αMβ2 integrin, the Bordetella adenylate cyclase toxin polypeptide inhibits (completely or partially) binding of the competitor antibody to a measurable extent. The inhibition of binding may be measured by any of the methods described above. In general, a Bordetella adenylate cyclase toxin polypeptide is considered to competitively inhibit binding of a competitor antibody, if binding of the competitor antibody to the antigen (αMβ2 integrin) is reduced by at least 30%, usually at least about 40%, 50%, 60% or 75%, and often by at least about 90%, in the presence of the Bordetella adenylate cyclase toxin polypeptide using any of the assays described above. In embodiments. where the Bordetella adenylate cyclase toxin polypeptide binds αMβ2 integrin, the polypeptide binds with a Kd of less than 1 μM. In embodiments. where the Bordetella adenylate cyclase toxin polypeptide binds αMβ2 integrin, the polypeptide binds with a Kd of less than 0.5 μM.
The sequences of the recombinant Bordetella adenylate cyclase toxin polypeptide provided herein may not include an acylated amino acid residue. Thus, in embodiments, the sequence is a non-acylated sequence. In embodiments, the sequence includes a non-acylated amino acid residue at a position corresponding to K983 or K860. In embodiments, the sequence includes a non-acylated amino acid residue at a position corresponding to K983. In embodiments, the sequence includes a non-acylated amino acid residue at a position corresponding to K860. In embodiments, the non-acylated residue is a lysine. In embodiments, the Bordetella adenylate cyclase toxin polypeptide does not bind αMβ2 integrin. In further, embodiments the sequence is a non-acylated sequence.
The Bordetella adenylate cyclase toxin polypeptide provided herein may not bind αMβ2 integrin. In embodiments, where the Bordetella adenylate cyclase toxin polypeptide does not bind αMβ2 integrin, the polypeptide or immunogenic fragment thereof is not internalized if bound to αMβ2 integrin expressed on the surface of a cell (e.g., leukocyte involved in the innate immune system, including monocyte, granulocyte, macrophage, and natural killer cell). In embodiments, where the Bordetella adenylate cyclase toxin polypeptide does not bind αMβ2 integrin, the polypeptide or immunogenic fragment thereof does not competitively inhibit the binding of a αMβ2 integrin antibody. Thus, the Bordetella adenylate cyclase toxin polypeptide that does not bind αMβ2 integrin may not recognize the same epitope as a αMβ2 integrin antibody. In embodiments. where the Bordetella adenylate cyclase toxin polypeptide does not bind αMβ2 integrin, the polypeptide does not bind with a Kd of less than 10 μM. In embodiments. where the Bordetella adenylate cyclase toxin polypeptide does not bind αMβ2 integrin, the polypeptide does not bind with a Kd of less than 5 μM. In embodiments. where the Bordetella adenylate cyclase toxin polypeptide does not bind αMβ2 integrin, the polypeptide does not bind with a Kd of less than 1 μM.
In one aspect a method for immunizing a subject in need thereof against Bordetella pertussis is provided. The method includes administering to the subject an effective amount of the vaccine as provided herein including embodiments thereof. In embodiments, the subject is a human. Method provided is performed under conditions such that antibodies directed to the recombinant Bordetella adenylate cyclase toxin polypeptide or immunogenic fragment thereof are produced. In embodiments, the antibodies prevent binding of Bordetella adenylate cyclase toxin protein of Bordetella pertussis, Bordetella bronchioseptica or Bordetella parapertussis to αMβ2 integrin. In embodiments, the antibodies are capable of binding adenylate cyclase toxin of Bordetella pertussis, Bordetella bronchioseptica or Bordetella parapertussis. In embodiments, the recombinant Bordetella adenylate cyclase toxin polypeptide fragment forms part of a vaccine.
The recombinant Bordetella adenylate cyclase toxin polypeptides as provided herein may be formulated and introduced as a vaccine through oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, and via scarification (scratching through the top layers of skin, e.g., using a bifurcated needle) or any other standard route of immunization. Vaccine formulations suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia), each containing a predetermined amount of a subject composition thereof as an active ingredient or any other oral composition as listed above. Alternatively, the vaccines may be administered parenterally as injections (intravenous, intramuscular or subcutaneous). Alternatively, recombinant Bordetella adenylate cyclase toxin polypeptides of the present invention may be encapsulated in liposomes and administered via injection. Commercially available liposome delivery systems are available from Novavax, Inc. of Rockville, Md., commercially available under the name Novasomes™. These liposomes are specifically formulated for immunogen delivery. The amount of recombinant Bordetella adenylate cyclase toxin polypeptides used in a vaccine can depend upon a variety of factors including the route of administration, species, and use of booster administration. However, a person of ordinary skill in the art would immediately recognize appropriate and/or equivalent doses looking at dosages of approved whopping cough vaccines for guidance.
The term “adjuvant” refers to a compound that when administered in conjunction with an antigen (e.g. recombinant Bordetella adenylate cyclase toxin polypeptide) augments the immune response to the antigen, but when administered alone does not generate an immune response to the antigen. Adjuvants can augment an immune response by several mechanisms including lymphocyte recruitment, stimulation of B and/or T cells, and stimulation of macrophages. The adjuvant increases the titer of induced antibodies and/or the binding affinity of induced antibodies relative to the situation if the immunogen were used alone. A variety of adjuvants can be used in combination with the recombinant Bordetella adenylate cyclase toxin polypeptides as provided herein, to elicit an immune response. Preferred adjuvants augment the intrinsic response to an immunogen without causing conformational changes in the immunogen that affect the qualitative form of the response. Preferred adjuvants include aluminum hydroxide and aluminum phosphate, 3 De-O-acylated monophosphoryl lipid A (MPL™) (see GB 2220211 (RIBI ImmunoChem Research Inc., Hamilton, Mont., now part of Corixa) or monophosphoryl lipid-A (/MPL) formulated with cationic dimethyldioctadecylammonium (DDA) liposomes (DDA/MPL). Further contemplated are oligodeoxynucleotides containing specific CpG motifs (CpG ODNs such as ODN 1826 and ODN 2006), synthetic analogs of double-stranded RNA such as Poly (I:C), Stimulon™ QS-21 is a triterpene glycoside or saponin isolated from the bark of the Quillaja Saponaria Molina tree found in South America (see Kensil et al., in Vaccine Design: The Subunit and Adjuvant Approach (eds. Powell & Newman, Plenum Press, N Y, 1995); U.S. Pat. No. 5,057,540), (Aquila BioPharmaceuticals, Framingham, Mass.), imidazoquinolines (i.e. imiquimod, gardiquimod and R848) and curdlan as a TH17 stimulating adjuvant. Other adjuvants are oil in water emulsions (such as squalene or peanut oil), optionally in combination with immune stimulants, such as monophosphoryl lipid A (see Stoute et al., N. Engl. J. Med. 336, 86-91 (1997)), pluronic polymers, and killed mycobacteria. Another adjuvant is CpG (WO 98/40100). Adjuvants can be administered as a component of a therapeutic composition with an active agent or can be administered separately, before, concurrently with, or after administration of the therapeutic agent.
Other examples of adjuvants are aluminum salts (alum), such as alum hydroxide, alum phosphate, alum sulfate. Such adjuvants can be used with or without other specific immunostimulating agents such as MPL or 3-DMP, QS-21, polymeric or monomeric amino acids such as polyglutamic acid or polylysine. Another class of adjuvants is oil-in-water emulsion formulations. Such adjuvants can be used with or without other specific immunostimulating agents such as muramyl peptides (e.g., N-acetylmuramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1′-2′dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (MTP-PE), N-acetylglucsaminyl-N-acetylmuramyl-L-Al-D-isoglu-L-Ala-dipalmitoxy propylamide (DTP-DPP) Theramide™), or other bacterial cell wall components. Oil-in-water emulsions include (a) MF59 (WO 90/14837), containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing various amounts of MTP-PE) formulated into submicron particles using a microfluidizer such as Model 110Y microfluidizer (Microfluidics, Newton Mass.), (b) SAF, containing 10% Squalene, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP, either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) Ribi™ adjuvant system (RAS), (Ribi ImmunoChem, Hamilton, Mont.) containing 2% squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphoryllipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL+CWS (Detox™).
Other adjuvants contemplated for the invention are saponin adjuvants, such as Stimulon™ (QS-21, Aquila, Framingham, Mass.) or particles generated therefrom such as ISCOMs (immunostimulating complexes) and ISCOMATRIX. Other adjuvants include RC-529, GM-CSF and Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA). Other adjuvants include cytokines, such as interleukins (e.g., IL-1 α and β peptides, IL-2, IL-4, IL-6, IL-12, IL13, and IL-15), macrophage colony stimulating factor (M-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), tumor necrosis factor (TNF), chemokines, such as MIP1α and β and RANTES. Another class of adjuvants is glycolipid analogues including N-glycosylamides, N-glycosylureas and N-glycosylcarbamates, each of which is substituted in the sugar residue by an amino acid, as immuno-modulators or adjuvants (see U.S. Pat. No. 4,855,283). Heat shock proteins, e.g., HSP70 and HSP90, may also be used as adjuvants.
An adjuvant can be administered with an immunogen as a single composition, or can be administered before, concurrent with or after administration of the immunogen. Immunogen and adjuvant can be packaged and supplied in the same vial or can be packaged in separate vials and mixed before use. Immunogen and adjuvant are typically packaged with a label indicating the intended therapeutic application. If immunogen and adjuvant are packaged separately, the packaging typically includes instructions for mixing before use. The choice of an adjuvant and/or carrier depends on the stability of the immunogenic formulation containing the adjuvant, the route of administration, the dosing schedule, the efficacy of the adjuvant for the species being vaccinated, and, in humans, a pharmaceutically acceptable adjuvant is one that has been approved or is approvable for human administration by pertinent regulatory bodies. For example, Complete Freund's adjuvant is not suitable for human administration. Alum, MPL and QS-21 are preferred. Optionally, two or more different adjuvants can be used simultaneously. Preferred combinations include alum with MPL, alum with QS-21, MPL with QS-21, MPL or RC-529 with GM-CSF, and alum, QS-21 and MPL together. Also, Incomplete Freund's adjuvant can be used (Chang et al., Advanced Drug Delivery Reviews 32, 173-186 (1998)), optionally in combination with any of alum, QS-21, and MPL and all combinations thereof.
Agents for inducing an immune response can be administered by parenteral, topical, intravenous, oral, subcutaneous, intraarterial, intracranial, intraperitoneal, intranasal or intramuscular means for prophylactic and/or therapeutic treatment. The most typical route of administration of an immunogenic agent is subcutaneous although other routes can be equally effective. The next most common route is intramuscular injection. This type of injection is most typically performed in the arm or leg muscles.
For parenteral administration, agents of the invention can be administered as injectable dosages of a solution or suspension of the substance in a physiologically acceptable diluent with a pharmaceutical carrier that can be a sterile liquid such as water oils, saline, glycerol, or ethanol. Additionally, auxiliary substances, such as wetting or emulsifying agents, surfactants, pH buffering substances and the like can be present in compositions. Other components of pharmaceutical compositions are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, and mineral oil. In general, glycols such as propylene glycol or polyethylene glycol are preferred liquid carriers, particularly for injectable solutions. Polypeptides can be administered in the form of a depot injection or implant preparation which can be formulated in such a manner as to permit a sustained release of the active ingredient. An exemplary composition comprises recombinant Bordetella adenylate cyclase toxin polypeptide at 5 mg/ml, formulated in aqueous buffer consisting of 50 mM L-histidine, 150 mM NaCl, adjusted to pH 6.0 with HCl. Composition for parenteral administration are typically substantially sterile, isotonic and manufactured under GMP conditions of the FDA or similar body.
Typically, compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection can also be prepared. The preparation also can be emulsified or encapsulated in liposomes or micro particles such as polylactide, polyglycolide, or copolymer for enhanced adjuvant effect, as discussed above (see Langer, Science 249, 1527 (1990) and Hanes, Advanced Drug Delivery Reviews 28, 97-119 (1997). The agents of this invention can be administered in the form of a depot injection or implant preparation which can be formulated in such a manner as to permit a sustained or pulsatile release of the active ingredient.
Additional formulations suitable for other modes of administration include oral, intranasal, and pulmonary formulations, suppositories, and transdermal applications.
For suppositories, binders and carriers include, for example, polyalkylene glycols or triglycerides; such suppositories can be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably 1%-2%. Oral formulations include excipients, such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, and magnesium carbonate. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10%-95% of active ingredient, preferably 25%-70%.
Topical application can result in transdermal or intradermal delivery. Topical administration can be facilitated by co-administration of the agent with cholera toxin or detoxified derivatives or subunits thereof or other similar bacterial toxins (See Glenn et al., Nature 391, 851 (1998)). Co-administration can be achieved by using the components as a mixture or as linked molecules obtained by chemical crosslinking or expression as a fusion protein.
Alternatively, transdermal delivery can be achieved using a skin path or using transferosomes (Paul et al., Eur. J. Immunol. 25, 3521-24 (1995); Cevc et al., Biochem. Biophys. Acta 1368, 201-15 (1998)).
In another aspect, a method of preventing or treating whooping cough in a subject in need thereof is provided. The method includes administering to the subject a therapeutically effective amount of the vaccine as provided herein including embodiments thereof.
The term “therapeutically effective amount” means the amount of the recombinant Bordetella adenylate cyclase toxin polypeptide that will elicit the biological or medical response of a cell, tissue, system, or animal, such as a human, that is being sought by the researcher, veterinarian, medical doctor or other treatment provider.
The term “vaccine excipient” as provided herein refers to any inactive substance appropriate as carried for active ingredients (e.g., a recombinant Bordetella adenylate cyclase toxin polypeptide) of a vaccine composition. Non limiting examples of a vaccine excipient include, acetone, alcohol, anhydrous lactose, castor oil, cellulose acetate phthalate, dextrose, D-fructose, D-mannose, FD&C Yellow #6 aluminum lake dye, fetal bovine serum, human serum albumin, magnesium stearate, micro crystalline cellulose, plasdone C, Polacrilin potassium, potassium phosphate, sodium bicarbonate, sucrose, aluminum hydroxide, amino acids, benzethonium chloride, formaldehyde, inorganic salts and sugars, vitamins, citric acid, lactose, glycerin, iron ammonium citrate, magnesium sulfate, beta-propiolactone, egg protein, neomycin, nonylphenol ethoxylate, polymyxin, thimerosal, and potassium phosphate. Acceptable vaccine excipients are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, or acetate at a pH typically of 5.0 to 8.0, most often 6.0 to 7.0; salts such as sodium chloride, potassium chloride, etc. to make isotonic; antioxidants, preservatives, low molecular weight polypeptides, proteins, hydrophilic polymers such as polysorbate 80, amino acids such as glycine, carbohydrates, chelating agents, sugars, and other standard ingredients known to those skilled in the art (Remington's Pharmaceutical Science 16th edition, Osol, A. Ed. 1980). The polypeptide is typically present at a concentration of 0.1-100 mg/ml, e.g., 1-10 mg/ml or 10-50 mg/ml, for example 5, 10, 20, 30, 40, 50 or 60 mg/ml.
A pharmaceutical composition including a recombinant Bordetella adenylate cyclase toxin polypeptide as described herein can be administered by a variety of methods known in the art. The route and/or mode of administration vary depending upon the desired results. In embodiments, administration is intravenous, intramuscular, intraperitoneal, or subcutaneous, or administered proximal to the site of the target. Pharmaceutically acceptable vaccine excipients can be suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or infusion).
Pharmaceutical compositions of the recombinant Bordetella adenylate cyclase toxin polypeptide can be prepared in accordance with methods well known and routinely practiced in the art. See, e.g., Remington: The Science and Practice of Pharmacy, Mack Publishing Co., 20th ed., 2000; and Sustained and Controlled Release Drug Delivery Systems, J. R. Robinson, ed., Marcel Dekker, Inc., New York, 1978. Pharmaceutical compositions are preferably manufactured under GMP conditions. Typically, a therapeutically effective dose or efficacious dose of the polypeptide is employed in the pharmaceutical compositions of the invention. The polypeptide can be formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art. Dosage regimens are adjusted to provide the optimum desired response (e.g., a therapeutic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It may be advantageous to formulate the recombinant Bordetella adenylate cyclase toxin polypeptide in combination with other therapies or agents. It can be advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of recombinant Bordetella adenylate cyclase toxin polypeptide calculated to produce the desired therapeutic effect in association with the required pharmaceutical excipient.
Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention can be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. The selected dosage level depends upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present invention employed, the route of administration, the time of administration, the rate of excretion of the polypeptide being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors.
A physician or veterinarian can start doses of the recombinant Bordetella adenylate cyclase toxin polypeptide of the invention employed in the pharmaceutical composition at levels lower than that required to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. In general, effective doses of the compositions of the present invention vary depending upon many different factors, including the specific disease or condition to be treated, means of administration, target site, physiological state of the patient, whether the patient is human or an animal, other medications administered, and whether treatment is prophylactic or therapeutic. Treatment dosages need to be titrated to optimize safety and efficacy. For administration with a polypeptide, the dosage ranges from about 0.0001 to 100 mg/kg, and more usually 0.01 to 5 mg/kg, of the host body weight. For example dosages can be 1 mg/kg body weight or 10 mg/kg body weight or within the range of 1-10 mg/kg. An exemplary treatment regime entails administration once per every two weeks or once a month or once every 3 to 6 months.
Recombinant Bordetella adenylate cyclase toxin polypeptides can be administered on multiple occasions. Intervals between single dosages can be weekly, monthly or yearly. Intervals can also be irregular as indicated by measuring blood levels of polypeptide in the patient. In some methods, dosage is adjusted to achieve a plasma polypeptide concentration of 1-1000 μg/ml and in some methods 25-300 μg/ml. Alternatively, polypeptides can be administered as a sustained release formulation, in which case less frequent administration is required. Dosage and frequency vary depending on the half-life of the polypeptide in the patient.
A. Experimental Procedures
Individual ACT domains were expressed in the bacterial cytoplasm of E. coli with His6-tags. To generate plasmids expressing only the catalytic domain (residues 1-373, 1-385 or 1-400), the corresponding coding regions were amplified from pT7CACT3 (29) by PCR, with common forward primer 5′-aggaaacaCATATGcagcaatcgcatcaggctgg-3′ (SEQ ID NO:19) and reverse primers 5′-actaGAATTCttacgaacgtccgctcggcacg-3′ (SEQ ID NO:20), 5′-cacaGAATTCttacgccggcaccgtttccagtacatc-3′ (SEQ ID NO:21), and 5′-cataGAATTCttactggcgttccactgcgcc-3′ (SEQ ID NO:22) respectively (restriction sites in uppercase and underlined). The amplified fragments were gel purified and double digested with NdeI and EcoRI and ligated into similarly digested pET28a vector. To generate plasmids expressing the RTX domains (residues 751-1706 or 985-1706), DNA fragments encoding these regions were amplified using forward primers 5′-tcacgaaCATATGgccaattcggacg-3′ (SEQ ID NO:23) and 5′-ctacggcCATATGacggagaatgtcca-3′ (SEQ ID NO:24), and common reverse primer 5′-ataGGATCCtcagcgccagttgacag-3′ (SEQ ID NO:25). The resulting PCR products were gel purified, double digested with NdeI and BamHI, and ligated into similarly digested pET28a vector.
To enhance folding and solubility, the hydrophobic domain, encompassing the region between the catalytic and RTX domains (residues 399-1096) was cloned into pMalc-5× vector (NEB) between NdeI and BamHI sites, downstream of the maltose binding protein (MBP). The primers for PCR were 5′-gggcgcaCATATGcgccaggattccggct-3′ (SEQ ID NO:26) and 5′-atcggcGGATCCttaatggtgatgatggtgatgggcgctggcctcggaaggctggtgcac-3′ (SEQ ID NO:27); with the bold nucleotides encoding a C-terminal His6-tag. The cyaC gene was inserted downstream of the hydrophobic domain between the BamHI and HindIII sites, with an upstream ribosome binding to allow for co-expression.
Full-length ACT was expressed from the plasmid pT7CACT3 with co-expression of the palmitoylating enzyme CyaC in Escherichia coli strain XL-1 Blue (29). The holo-toxin was purified using a single-step calmodulin agarose affinity chromatography as described by Sebo et al. (2) Purified ACT was stored in 50 mM Tris, 8M urea, 2 mM EDTA, pH 8.0 at 4° C. for short term or −80° C. for long term storage. The protein concentration was determined by absorbance at 280 nm using a molecular extinction coefficient of 143590 M−1cm−1 as calculated from its amino acid sequence (30). ACT from BEI Resources was used as a reference for purity and toxicity.
The catalytic and RTX domains of ACT were expressed in E. coli strain BL21(DE3). Briefly, 250 mL of TB media were inoculated from starter cultures to an optical density at 600 nm (OD600) of 0.05, grown at 37° C. until OD600=0.3-0.6, at which time 0.4 mM IPTG (isopropyl-β-D-thiogalactopyranoside) was added to induce expression. After 4 h of room temperature growth, the cells were harvested, resuspended in Buffer A (50 mM Hepes, 250 mM NaCl, 2 mM CaCl2, 40 mM imidazole, pH 8.0), and lysed with a French Press (Thermo Scientific). After a 20 min centrifugation step at 20,000 rpm (JA-20 rotor), the supernatant was applied to a HisTrap column on an AKTA FPLC (GE healthcare), followed by elution with a linear gradient of Buffer B (Buffer A+500 mM imidazole). The hydrophobic domain was expressed in E. coli strain BL21 as above, although purification included immobilized metal affinity chromatography (IMAC) resin followed by an MBPTrap affinity column (GE healthcare) and elution with 10 mM maltose.
To assess the oligomeric status of ACT and its domains, fractions eluted from Histrap or IMAC were supplemented with either 100 μL of 100 mM EGTA or 100 mM HBSC (HBS+2 mM CaCl2), incubated on ice for 1 hr, and loaded onto Superdex S200 column equilibrated with HBS (50 mM Hepes, 150 mM NaCl, pH 7.8) or HBSC, respectively. Running buffers were HBS or HBSC to ensure the absence or presence of calcium ion. To assess secondary structure characteristics, purified ACT domains were dialyzed into 10 mM Tris-H2SO4 pH8.0 and the concentrations were adjusted to 100 μg/mL. To observe the effect of calcium ions on protein conformation, CaCl2 were added to a final concentration of 2 mM and incubated at room temperature for 1 h. CD spectra between 180-260 nm were collected on a J-815 CD Spectrometer (JASCO) at 25° C., at lnm intervals using a 1 mm rectangular cell. Each spectrum represents the average of 3 scans subtracted with the spectrum of buffers (with or without CaCl2). Data were fitted with the CDSSTR program on the DichroWeb server to estimate the percentage of secondary structures (31).
All protocols were approved by the University of Texas at Austin IACUC (protocol #2012-00068) and all mice were handled in accordance with IACUC guidelines. As a source for antibody libraries, two 6-week BALB/c mice were primed intraperitoneally (i.p.) with 17 μg of ACT (dialyzed against PBS to remove urea) in complete Freud's adjuvant (CFA). Four weeks later, the mice were bled through tail vein, and boosted subcutaneously with the same amount of PBS-dialyzed ACT in incomplete Freund's adjuvant (IFA). Two weeks later, the mice were sacrificed and blood collected by cardiac puncture. Spleens were removed sterilely, sliced into pieces and immediately immersed in 1 ml of cold RNALater solution. After soaking overnight at 4° C., the solution was removed and the spleens were stored at −80° C.
To assess the immunogenicity of individual ACT domains, 4-6 BALB/c mice per group were immunized subcutaneously with equal moles of ACT and individual domains (10 μg for ACT, 2.6 μg for 1-400, 6.7 μg for 399-1096, and 4.4 μg for 985-1706) in complete Freund's adjuvant. Four weeks later, the mice were boosted subcutaneously with the same amount of antigen in incomplete Freud's adjuvant, a process which was repeated at 6 and 8 weeks. Blood was collected before immunization, four weeks after the first injection, and two weeks after each boost. Anti-ACT antibody titers were determined by ELISA (described below), with titer defined as the 50% effective concentration (EC50) from a 4-parameter logistic fitting to the ELISA data. Neutralization of ACT-induced cAMP intoxication of J774A.1 macrophage cells (ATCC #TIB-67) was tested with a 1:400 sera dilution.
Total RNA was extracted from frozen spleens with TRIZol (Invitrogen) and the RNeasy Mini Kit (QIAgen) or PureLink RNA kit (Invitrogen) according to the manufacturers' instructions. The quality and concentration of total RNA was assessed by agarose gel electrophoresis and A230:260:280 ratio (approximately 1:2:1 for pure RNA) measured by NanoDrop 2000 (Thermo Scientific). For first-strand cDNA synthesis, 5 μg of total RNA was used. To maximize diversity, two separate reactions were performed using combinations of Superscript II+d(T)23 VN primer or Superscript III (Invitrogen)+random hexamer (Thermo Scientific), following manufacturers' instructions. The two sets of cDNA were pooled as template for amplification of the VL and VH repertoires using the primer sets and PCR conditions described by Krebber et al. (32). The PCR products were gel purified, with 10 ng each of VL and VH used as template in an overlap PCR to generate VL-linker-VH fragments (scFv). This product was gel purified and digested overnight with SfiI prior to directional ligation with similarly SfiI-digested pMopac24 vector (33). Ten individual electroporations were performed to transform XL1-Blue cells. The transformants were pooled and an aliquot was 10-fold serially diluted and plated to count library size; the rest were plated on eight 150 mm 2×YT agar plates (10 μg/mL tetracycline, 200 μg/mL ampicillin, and 2% glucose). After incubation overnight at 37° C., the bacterial lawns were scraped off in 2×YT medium and pooled to form the master library.
Aliquots of the master library was used to inoculate 250 mL 2×YT medium with 10 μg/mL tetracycline, 200 μg/mL ampicillin, and 2% glucose in 1 L flasks to an OD600 of ˜0.1. The cultures were grown at 37° C. for 2-3 hours until the OD600 reached ˜0.6, induced and rescued by adding 1 mM IPTG and M13K07 helper phage (MOI ˜20), incubated for 30 min without shaking at 37° C., and then returned to a shaking incubator at room temperature. Three hours after adding helper phage, the culture was supplemented with 50 μg/mL kanamycin prior to overnight incubation with shaking. Phage were then purified by double precipitation with 1/5 volume of precipitation solution (2.5M NaCl, 20% PEG-8000). The concentration of viable phage was assessed as colony forming units (cfu), with serially diluted phage added to log-phase XL1-Blue cells, followed by plating on 2×YT agar plate with 200 μg/mL ampicillin, and enumeration of colonies after overnight incubation.
Two rounds of panning were performed using ACT as bait. Eight ELISA plate wells (Costar) were coated with 50 μL of 2 μg/mL and 1 μg/mL ACT in PBS at 4° C. overnight for the first and second round respectively. Input phage (100 ul) were diluted into 900 ut of 5% non-fat milk in PBST (PBS, 0.05% Tween-20) and incubated for 1 h before transferring 100 μL to each of the 8 wells. After a 1 hour incubation at room temperature, followed by five (or ten for round 2) washes with PBST, bound phage were eluted with 100 μL per well of 0.1 N HCl for 10 min at RT. The eluted phage was pooled and immediately neutralized with 48 μL of 2M Tris base. Half of the output phages were added into 5 ml of log-phase XL1-Blue culture grown with 10 μg/mL tetracycline at 37° C. to retain the F plasmid, incubated for 30 min without shaking and 1 hr with shaking at 225 rpm in 37° C., then spun down and plated on six 150 mm 2YT agar plate (200 μg/mL ampicillin, 10 μg/mL tetracycline, and 2% glucose). After overnight incubation at 37° C., colonies or lawn were scraped, pooled, mixed thoroughly, and aliquots used for second round of panning as described above.
Input and output phage titers (colony forming unit, cfu) were determined by infecting and plating E. coli as described above. Sequence diversity was monitored throughout all steps by performing colony PCR of random colonies on the phage titration plates, followed by BstNI fingerprinting and agarose gel electrophoresis. Clones with unique fingerprints were confirmed by DNA sequencing.
To produce monoclonal phage clones from panning outputs, single colonies from output plates were inoculated into sterile 96-well plate containing 100 μL 2YT medium (2% glucose, 200 μg/mL ampicillin, and 10 μg/mL tetracycline), grown at 37° C. overnight with shaking. The next morning, 10 μL of the overnight culture was inoculated into another plate with 90 μL per well of fresh medium containing 0.25% glucose and antibiotics, grown at 37° C. for 3 hr, then 50 μL 2YT (200 μg/mL Amp, 3 mM IPTG, and M13K07 helper phage) was added and let shaking at room temperature for 3 hours, before adding 50 μL of 2YT (200 μg/mL ampicillin, 1 mM IPTG, 200 μg/mL kanamycin). The plate was then shaken at room temperature overnight.
To convert phage-displayed scFvs to soluble single chain antibody fragments (scAbs), consisting of a variable light chain domain (VL) connected via a flexible (Gly4Ser)4 to a variable heavy chain domain (VH) followed by a human kappa constant domain to enhance expression and solubility, the scFv region was removed from pMopac24 phagemid vector by SfiI digestion, and directionally ligated into SfiI-digested pMopac54 plasmid (34). For scAb production, 100 ml of TB supplemented with 200 μg/mL ampicillin and 1% glucose were inoculated at OD600=0.02, grown overnight at room temperature. The next morning, cells were pelleted at 5000 g for 10 min at room temperature, resuspended in 100 ml of TB medium with ampicillin but no glucose, and grown at room temperature for 1 h before induction with 1 mM IPTG. After another 4 hours, cells were harvested by centrifugation at 5000 g, 10 min, 4° C. Osmotic shock was performed as described (34). scAbs in the dialyzed shockates were purified by IMAC resin followed by size exclusion chromatography with a Superdex 200 column on FPLC (GE Healthcare). Protein concentrations were measured by BCA assays (Pierce) using a BSA standard with purity assessed by SDS-PAGE.
To convert scAbs into full-length IgG with enhanced stabilities and in vivo half-lives, the VL and VH genes were subcloned onto Igκ-Abvec and IgG-Abvec vectors as described by Smith et al. (35). For IgG production, paired Igκ-Abvec and IgG-Abvec plasmids were transiently transfected into CHO-K1 cells using Lipofectamine 2000 (Life Technologies) according to manufacturer's instructions. Culture media were collected at 1-2 day intervals, neutralized with 1M Tris pH 8.0, pooled, and IgG purified by ammonium sulfate precipitation followed by HiTrap Protein A column. The purity and presence of aggregates were assessed by SDS-PAGE and size-exclusion chromatography using a Superdex S200 column. The concentration was determined by A280 using extinction coefficients calculated from deduced amino acid sequences (30).
For monoclonal phage screening, the 96-well phage production plates described above were spun at 3000 g for 20 min, with 40 μl of supernatant transferred to a coated (2 μg/ml ACT in PBS) and blocked (5% nonfat milk in PBST, M-PBST) ELISA plate containing 60 μL M-PBST per well, and incubated at room temperature for 1 hr. After 4 washes with PBST, 50 μL of 1:2000 HRP-conjugated anti-M13 antibody (GE Healthcare) was added, and incubated 1 hr at room temperature. The plate was washed 4 times, 50 μL/well TMB substrate added and incubated at room temperature. The reaction was quenched by adding 504/well 1M HCl, and the absorbance at 450 nm recorded with a SpectraMax M5 (Molecular Devices). Wells with absorbance higher than 2-fold of background were identified for further characterization.
Binding assays to assess domain specificity and relative affinity of soluble scAb or IgG proteins were performed in a similar manner. Purified ACT (1 μg/mL) or domains (equimolar with ACT) were coated on ELISA plates, followed by blocking and serial dilutions of purified antibodies, and finally detection with goat anti-mouse IgG HRP-conjugated antibody (to detect murine antibodies), goat anti-human κ chain HRP-conjugated antibody (to detect scAbs) or goat anti-human IgG (Fc-specific) HRP-conjugated antibody (to detect recombinant IgG). For competition ELISA, the antibody of interest was used at a fixed concentration determined to yield 70-80% of the maximal signal, and mixed with an equal volume of serially diluted competitor antibody, followed by detection as above.
To assess the reactivity of sera from humans exposed to pertussis, purified ACT (1 μg/mL) or domains (equimolar concentrations as ACT) were coated on ELISA plates. Plates were blocked as above, human sera serially diluted in M-PBST, and bound antibodies detected with goat anti-human IgG (Fc-specific) HRP-conjugated antibody. Nine randomly selected samples were tested in duplicate. The absorbance value for each sample binding to a domain was normalized to that sample's signal on an ACT-coated well at a 100-fold dilution (in the linear dose-response range) as follows: [A450(domain coated well)−A450(uncoated well)]/[A450(ACT coated well)−A450(uncoated well)]. Human sera were obtained from Vanderbilt University Medical Center under a protocol approved by the local institutional review board (IRB 061262, 070258 and 090806). Use of those samples was approved by the University of Texas at Austin (2009-05-0096). The study was conducted in accordance with the Declaration of Helsinki, with written informed consent obtained from each participant prior to study entry. The original consent forms allowed for sample use in subsequent studies. CaCl2 levels in all ELISA assays were maintained at >2 mM unless indicated and each assay was performed at least twice.
In Vitro cAMP Intoxication & Neutralization Assay
J774A.1 cells were grown in DMEM (Sigma) supplemented with 10% fetal bovine serum, 1 mM sodium pyruvate, and penicillin/streptomycin. To measure the cAMP intoxication of J774A.1 cells by ACT or antibody neutralization, J774A.1 cells were seeded at 4×104/cm2 in 24-well plates (Costar) one day before the assay. ACT alone or with antibodies was diluted in DMEM without supplements in a final volume of 1 mL; base DMEM media contains 1.8 mM CaCl2. ACT was used at 125 ng/mL in all assays unless otherwise specified; antibodies were present at 160-fold molar excess. While ACT and antibody mixtures incubated at room temperature for 30 min, cells were washed twice with plain DMEM prior to addition of 480 μL of antibody-ACT solution to duplicate wells. The plate was incubated at 37° C. for 30 min in a CO2 incubator, followed by two washes with cold PBS. Lysis solution (500 μL; 0.1N HCl, 0.1% Triton X-100) was added into each well, and plate was rocked on ice for 10 min. The lysates were transferred into 1.5 ml tubes and boiled for 10 min to inactivate ACT and cAMP hydrolyzing enzymes. To assess cAMP intoxication in CHO cells, ACT was used at 250 ng/mL, with all other assay conditions kept constant.
The resulting lysates were clarified by centrifugation at 13,000 g for 5 min. The supernatant was diluted 6-fold with 200 mM Hepes, 150 mM NaCl, 0.05% Tween, pH 8.0 prior to cAMP measurement using a competition ELISA as described by Karimova et al. (36). All assays were performed at least in duplicate, with cAMP concentrations normalized to total protein concentration in the lysates as measured by BCA assay (Pierce).
To evaluate ACT neutralization in the context of the whole bacterium, B. pertussis Tohama I was grown on Bordet Gengou agar plate supplemented with 15% defibrinated sheep blood (BD) at 37° C. for 4 to 5 days. Bacteria were then inoculated into modified synthetic Stainer-Scholte medium (SSM) and grown at 37° C. with shaking at 225 rpm for 20˜24 h, to an OD600 of 0.7˜1.0. Bacteria were pelleted by centrifugation at 5,000 g for 10 min, resuspended in PBS, and diluted to an OD600 of 0.4 in DMEM+10% heat-inactivated (HI) FBS; then mixed with equal volume of serially diluted neutralizing or control IgGs in DMEM+10% HI-FBS, and incubated at room temperature for 20 min before addition to adherent J774A.1 cells and incubation of 1 hr at 37° C. Intracellular cAMP level was then measured as above.
Cell lysis was monitored by enzymatic activity of lactate dehydrogenease released into the medium upon cell lysis. J774A.1 cells were seeded 105 cells/well in 96-well round-bottom plates one day before the assay. 100 μL each of ACT alone (0.5 μg/mL) or ACT pre-incubated with antibodies (10 μg/mL, 160-fold molar excess antibody) in plain DMEM were added to triplicate wells and incubated for 2 hrs at 37° C. Then the plate was centrifuged at 250 g for 5 min and LDH activity in the supernatants were measured by a colorimetric assay with the CytoTox 96 kit (Promega, Wis., USA). After subtracting the background signal from control wells without ACT, the sample absorbance at 490 nm was normalized to ACT-only controls as follows: 100%*[A490 (ACT+antibody)−A490 (no ACT)]/[A490 (ACT only)−A490 (no ACT)].
Recombinant murine αMβ2 integrin (R&D Systems) was coated at 1 μg/mL in PBS at 4° C. overnight, and blocked with M-PBST. ACT or purified domains were serially diluted and incubated for 1 h at room temperature, followed by detection with polyclonal rabbit anti-ACT antibody and HRP-conjugated goat anti-rabbit antibody. To assess the effect of antibodies on ACT binding to integrin, ACT (1 μg/mL) was mixed with equal volume of serially diluted antibody (5, 1.6, 0.5 and 0-fold molar excess) and incubated for 1 h at room temperature before transferring to blocked αMβ2 ELISA plate. The bound ACT was detected as described above.
ACT was dialyzed against HBSC (50 mM Hepes, 150 mM NaCl, 2 mM CaCl2 pH 8.0) to remove urea, and then biotinylated with 100-fold molar excess of EZ-Link Sulfo-NHS-LC-Biotin (Thermo Scientific) at room temperature for 2-3 h before quenching with 1M Tris (pH 8.0) and dialysis against HBSC overnight in 4° C. Biotinylated ACT (B-ACT; 210 μL of 0.8 μg/mL) was incubated with equal volume containing 60 μg/mL purified scAb (M2B10, M1H5, M1F11, and M1C12) in DMEM+1% BSA at room temperature for 30 min. Then, 2004 of the incubated mixtures was added to 4×105 washed J774A.1 cells in duplicate, and incubated on ice for 30 min to allow ACT binding but not internalization. After two washes with FACS buffer (HBSC+2% FBS), 2004 of 1:500 phycoerythrin (PE)-conjugated Streptavidin (BioLegend) was used to detect cell-associated biotinylated ACT. After 20 min incubation on ice and three washes, the cells were finally resuspended in 6004 FACS buffer and analyzed on an LSR Fortessa II. Data analysis was performed with Flowjo software (V10).
B. Results
The native ACT holotoxin secreted from B. pertussis readily aggregates at the bacterial surface and is prone to proteolytic degradation (28), while recombinant toxin expressed in the E. coli cytoplasm forms inclusion bodies (37-39). To increase the yield of purified protein, 8M urea is used to extract the aggregated protein from bacterial cell pellets; even so the protein is highly susceptible to proteolysis with early reports observing enzymatic activity in 43 and 45 kDa fragments (40). Efforts to remove urea, such as dialysis and dilution, result in significant aggregation and fragmentation (41).
As a result, standard purification protocols include solubilization of the cell pellet with urea, followed by calmodulin affinity or sequential anionic and hydrophobic interaction chromatographic steps followed by storage in 8M urea. Assays using the toxin call for dialysis or dilution of urea-solubilized ACT into assay media immediately before experimentation, most likely resulting in an ensemble of fully and partially folded ACT molecules and uncertainty regarding the exact concentration of active toxin molecules. ACT purified in our lab exhibited similar activity as that described by Eby et al (42): 125 ng/mL produced 10,000˜40,000 pmoles cAMP per mg of J774A.1 total cellular protein in 30 min at 37° C.
However, dialysis or dilution of ACT into buffer with no urea led to protein that was poorly behaved and retained by the SEC column (<5% of protein applied to the column eluted). In contrast, overnight dialysis into HBSC containing 1 M urea resulted in high molecular weight aggregates (˜600 kDa) that eluted off the SEC column. An alternate refolding approach, rapid 10-fold dilution into HBSC (final urea concentration 0.8 M) followed immediately by SEC, yielded a broader aggregate peak and a smaller peak corresponding to the expected size for monomer (
To identify which, if any, ACT domains are predominantly recognized by polyclonal antibody responses, we expressed individual domains in E. coli with affinity tags to facilitate purification (Table 1). Based on prior reports (18,29,44-46), the n-terminal catalytic domains (residues 1-373 [CAT373], 1-385 [CAT385] and 1-400 [CAT400]) and c-terminal RTX domains (residues 751-1706 [RTX751] and 985-1706 [RTX985]) were cloned into the pET28a vector for cytoplasmic expression with n-terminal His6 tags to facilitate purification. In our hands, RTX482-1706 was poorly soluble and purified inefficiently; instead we selected RTX985 as the largest fragment to exclude both acylation sites but retaining the N-terminus before the first Gly-Asp rich repeat. To enhance solubility, the hydrophobic domain (residues 399-1096 [HP1096], encompassing the region between the catalytic and RTX domains) was fused downstream of maltose binding protein (MBP), with a c-terminal His6 tag and di-cistronic expression of the specific acylating enzyme CyaC (indicated by *). After cytoplasmic expression of each construct and cell lysis, a one-step affinity chromatography with a HisTrap column yielded ˜5-80 mg protein per liter culture with >90% purity as determined by SDS-PAGE (
To determine whether the purified domains exhibited native-like structure and expected calcium-dependent structural changes, size exclusion chromatography (SEC) was used to assess the oligomeric state while circular dichroism (CD) spectroscopy was used to assess the secondary structure content. The catalytic domains eluted as a single peak of expected size (40 kDa) with the estimated composition of secondary structures (56% helix, 14% strands, 13% turns and 17% unordered) similar to that determined by X-ray crystallography (
The hydrophobic fusion proteins eluted as broad aggregate peaks when acylated or non-acylated. In the absence of acylation, multiple smaller peaks were observed, suggesting that acylation may stabilize folding of this domain and protect against proteolysis. In both cases, the CD spectra were not characteristic of unfolded or aggregated proteins (
The solubility and CD spectra of these constructs may be dominated by the MBP fusion partner, but we did not attempt to remove it, as a shorter hydrophobic domain was reported to further aggregate under these circumstances (48).
The RTX domain comprises ˜40 RTX motifs, grouped into five blocks of calcium binding Gly-Asp repeats, separated by non-RTX flanking regions (
Theorizing that these two forms are a consequence of the missing acylation sites, we generated a larger construct to include both sites. RTX751 expressed without CyaC eluted as a single peak of expected size (˜110 kDa) in the presence or absence of calcium. When co-expressed with CyaC, presumably resulting in acylation at residues K860 and K983, RTX751* exhibited a calcium-dependent conversion from a soluble higher-molecular weight aggregate (˜600 kDa) to a compact monomer (˜90 kDa) in the presence of calcium (
The catalytic and RTX domains retain much of the expected structural behavior, with RTX751* appearing to better stabilize the monomeric form than RTX985. Similar to previous reports on ACT behavior (26,27,51-53), the presence of calcium and acylation appears to stabilize the RTX monomers. Anecdotally, the RTX domains were stable for at least six months at 4° C. with minimal aggregation or degradation (RTX751 and RTX751* were slightly more stable than RTX985), as measured by SDS-PAGE and SEC to assess the monomeric fraction. While the CAT400 domain also remains monomeric, it starts to degrade after three months under the same conditions, as measured by SDS-PAGE. The compact β-roll structure RTX domains adopt in the presence of calcium may contribute to their overall higher melting temperature and resistance to proteolysis than CAT (Table 1).
To determine if our domain constructs retain structural elements present in ACT, we screened a panel of nine previously characterized monoclonal antibodies for binding to ACT and individual domains by ELISA (47). All nine antibodies tested recognized only the expected domain and did not distinguish between acylated and non-acylated domains (Table 2), supporting the notion that they are properly folded. One exception is 2B12, whose epitope includes residues 888-1006, did not recognize HP1096. This may be due to incomplete folding of HP1096 or the binding site may require additional residues distal to residue 1006 not present in this construct.
As the RTX domain harbors the receptor binding site between residues 1166-1281 (26), we assessed the ability of our RTX constructs to bind purified murine extracellular αMβ2 receptor, a known ACT cell-surface receptor (25). While ACT and RTX751* both bound the murine receptor when acylated and in the presence of calcium (apparent EC50 ˜20 nM;
To determine whether a single ACT domain dominates the immune response, we used phage display to analyze murine antibody repertoires after ACT immunization. Two mice were immunized intraperitoneally with 17 μg of ACT in complete Freund's adjuvant and boosted subcutaneously once with incomplete Freund's adjuvant. The resulting sera neutralized the toxic activities of ACT at a 1:400 dilution in an in vitro cAMP intoxication assay. The spleens were harvested, and each was used to construct an antibody phage-display library, each containing ˜107 total transformants. After two rounds of panning against ACT, 90 individual clones from each library were grown in 96-well plates and assessed for ACT binding by phage ELISA. Of these, 57 and 60 clones from the two libraries respectively yielded signals two-fold above background, with 29 and 21 expressing unique sequences, as determined by BstNI fingerprinting and DNA sequencing.
To determine the domain specificities of unique antibodies, monoclonal phage were assessed for binding to individual domains in ELISA (
Next, we screened unique antibodies identified from phage libraries for the ability to neutralize ACT activities using an in vitro cAMP assay. There are several steps during ACT intoxication of cells which are susceptible to antibody-mediated neutralization—including receptor binding, membrane insertion, and translocation—interference with any of these will be reflected in decreased intracellular cAMP accumulation in or reduced lysis of target cells. For this assay, we employed the murine macrophage cell line J774A.1 bearing the αMβ2 integrin.
For the neutralization assay, antibodies were expressed as recombinant single-chain antibody fragments (scAb), comprised of the variable light chain (VL) joined to a flexible (Gly4Ser)4 linker and the variable heavy chain (VH), followed by a C-terminal human kappa chain constant region to increase solubility and serve as a detection handle (9). Based on multiple sequence alignment, 31 antibodies with unique CDR sequences were selected for scAb expression (
To identify antibodies neutralizing ACT function, ACT and individual scAbs were incubated at a 1:160 molar ratio before addition to adherent J774A.1 cells and determination of intracellular cAMP levels by competition ELISA. Of the 21 scAbs tested, nine reduced the cAMP level by more than 90%, as compared to cells treated with ACT alone, which we consider highly neutralizing in this assay (
We next sought to classify neutralizing antibodies based on their recognition of unique or overlapping epitopes. Here, we used a competitive binding ELISA, in which a single phage-displayed antibody was mixed with buffer or a second antibody in the scAb format, added to an ELISA well coated with ACT, followed by detection of bound phage remaining in the well. Reduced signal in the presence of a second antibody compared to phage antibody alone indicates competition between the two antibodies for the same or overlapping epitopes. Using this approach, the nine neutralizing antibodies were divided into two groups binding non-overlapping epitopes, while non-neutralizing antibodies recognized four unique epitopes, for a total of six epitopes represented in this study (
One representative antibody binding each neutralizing epitope was selected based on sequence uniqueness, expression level, and binding affinity for conversion into a full-length chimeric immunoglobulin, with human IgG1 and kappa constant domains (
To determine whether the antibodies identified here bind epitopes overlapping with those of previously defined murine monoclonal antibodies (47), we performed a second set of competition ELISAs (
Together, we observed antibodies binding six non-overlapping epitopes on RTX, two neutralizing and four non-neutralizing and all but two requiring the presence of calcium (
ACT primarily targets cells bearing the αMβ2 receptor under conditions in which the RTX domain assumes a receptor-binding competent conformation mediated by the presence of calcium ions and post-translational acylation (26). Combining this with our observation that the M2B10 and M1H5 antibodies showed a much weaker neutralizing effect at the same 160-fold molar excess when CHO-K1 cells lacking this receptor were used than when J774A.1 cells expressing the receptor were used (
To test this hypothesis, we used flow cytometry to monitor ACT bound to J774A.1 cells in the presence or absence of the M2B10 or M1H5 scAb. Biotinylated ACT was incubated with a 120-fold molar excess of neutralizing or non-neutralizing scAbs, added to J774A.1 cells and detected with phycoerythrin-conjugated streptavidin by FACS. The M2B10 and M1H5 antibodies significantly reduced binding of ACT-biotin to J774A.1 cells, while two non-neutralizing control scAbs (M1F11 and M1C12) had no significant effect (
To further confirm that the diminished binding of ACT to J774A.1 cells was due to interference with a specific receptor, a competition ELISA with soluble αMβ2 integrin was performed. ACT (0.5 μg/mL) was incubated with the M2B10, M1H5, M1F11 or 3D1 antibodies in molar ratios ranging from 5 to 0.5 and transferred to an αMβ2 integrin-coated plate. The result was consistent with the flow cytometry assay: M2B10 and M1H5 reduced ACT binding to immobilized αMβ2 integrin in a dose-dependent manner, >90% at a two-fold molar excess (
To determine whether ACT neutralization occurs in the context of the whole bacterium, we repeated this assay with live B. pertussis instead of purified ACT. According to Gray et al., newly synthesized ACT is responsible for intoxication (28). Therefore, B. pertussis was washed in PBS to remove any secreted ACT. Bacteria (OD600=0.2) added to J774A.1 cells resulted in cAMP levels similar to that induced by 125 ng/mL purified ACT. When the M2B10 and M1H5 but not the non-neutralizing M1F11 or 7C7 (58) antibodies were added with the bacteria, they resulted in dose-dependent reduction of cAMP levels (
To determine if any ACT domain dominates the immune response, we immunized mice with ACT and tested the resulting sera four weeks after primary immunization for binding to different ACT domains. Interestingly, strong responses were observed for ACT, RTX985 and RTX751, but no responses were observed for the CAT400 or HP1096* domains (
To determine whether this was the result of RTX immunodominance or a lack of immunogenicity by the CAT and HP domains, we immunized additional groups of mice with CAT40, HP1096* or RTX985. Here, RTX985 was selected since it shares many features with RTX751*, including recognition by at least one neutralizing antibody, yet lacks the acylation sites rendering it simpler to produce and less likely to engage the native receptor. The calcium concentration in extracellular fluid in the body is 2.2˜2.7 mM (59), which is sufficient to support bacterial secretion and folding of ACT during an infection and expected to support proper folding during immunization.
Mice immunized with ACT or RTX985 showed high anti-ACT titers four weeks after the first injection, which increased after boosting (weeks 6 and 8,
Next, we wanted to determine which domains induced sera best able to neutralize ACT cAMP intoxication activities in vitro with J774A.1 cells. Here, only immunization with RTX985 elicited sera able to protect cells to a similar extent as sera elicited by full-length ACT (
Finally, to determine whether humans show a similar bias towards RTX recognition, we tested nine serum samples from humans exposed to B. pertussis, selected randomly from a larger collection (62). All nine sera recognized RTX751 at a similar level as full-length ACT, while sera from only one individual bound CAT (
C. Discussion
The recent surge in pertussis cases, coupled with increasing recognition of the current acellular vaccine's shortcomings has motivated design of third generation vaccines to prevent pertussis. In humans, even a single dose of whole cell vaccine significantly reduces the risk of illness (63), while in baboons, acellular immunization prevented the severe symptoms of disease, but allowed bacterial persistence and transmission to naïve animals (5). In order to design future vaccines which minimize sub-clinical disease and reduce transmission to susceptible infants, it is crucial to understand the roles played by various protective antigens. ACT has been shown to be protective in animal models and is immunogenic in humans (15,16,40,64,65). Since ACT activities hinder local anti-bacterial immune responses (66-68), anti-ACT antibodies may protect these cells, indirectly facilitating bacterial elimination. Here, we demonstrated that the RTX domain is able to largely recapitulate the protective humoral immune response induced by ACT in mice and is better expressed and more stable than the intact ACT.
ACT was first discovered based on its ability to increase cAMP levels in neutrophils, inhibiting their anti-bacterial functions, including phagocytosis and respiratory burst and promoting the early stages of disease establishment (66). At physiologically relevant concentrations (<50 ng/ml) (69), ACT results in cytotoxicity to the murine macrophage cell line J774A.1 after two hours exposure; IL-2 secretion and proliferation of T cells and chlorine efflux from polarized epithelial cells (42). More recently, ACT has been shown to suppress development of an IL-17 mediated immune response which appears key for bacterial clearance (21). As a result, passively administered antibodies blocking ACT function may be able to enhance neutrophil-mediated phagocytosis of opsonized bacteria (67). Murine studies have shown that immunization with ACT alone or as a supplement to the acellular vaccine reduces bacterial colonization, an effect which correlated with increased immunoglobulin levels and a Th1/Th2 cytokine phenotype (16,54). Finally, ACT is a highly conserved antigen, able to induce protective immunity in mouse models against the three dominant Bordetella species (B. pertussis, B. parapertussis, and B. bronchiseptica) (70-72). While ACT is unlikely to be highly protective as an isolated antigen, it may be a valuable addition to vaccines.
The complex mechanism by which ACT directly translocates its catalytic domain into the host cell cytosol remains incompletely understood. The current working model consists of three steps (48,73,74). First, in the presence of millimolar levels of calcium and acylation, the RTX domain forms a beta barrel which binds the αMβ2 receptor on neutrophils or the β2-containing integrin LFA receptor on T cells through N-linked oligosaccharides. Second, this is followed by insertion of two loops (four predicted transmembrane alpha helices between residues 502-522 and 565-591) into the host cell membrane, resulting in a translocation intermediate which permeabilizes the membrane to allow an influx of extracellular calcium ions, activating calpain-mediated cleavage of the integrin's talin tether. Third, the ACT-receptor complex is then free to diffuse to cholesterol-rich lipid rafts, which triggers complete translocation of the catalytic domain dependent on residues 375-485 (48). Interestingly, no specific sequence contained in the catalytic domain is required for translocation, allowing this region to be replaced with other sequences for intracellular delivery (75).
This structure-function information provides insight into epitopes required for cellular intoxication and those likely to induce protective responses. For instance, antibodies could block translocation steps, yet only one such antibody has been characterized. Immunization with ACT, followed by analysis of the resulting polyclonal serum suggested that antibodies recognizing the RTX domain dominate the response, as 6 of 12 monoclonal antibodies recognized this domain (47,72). Of these, the 3D1 antibody binds a conformational epitope between residues 373-399, adjacent to the catalytic domain, apparently trapping a translocation intermediate and preventing complete delivery of the catalytic domain to the host cytosol (48,73), while the anti-hydrophobic region antibody 2A12 inhibits intoxication and to a lesser extent, hemolysis, and the anti-RTX antibody 6E1 inhibits only hemolysis (47). Consistent with these prior reports, we observed that the majority of antibodies recovered from phage libraries bind the RTX domain, while sera from four mice immunized with the holo-toxin bind RTX only. To the best of our knowledge, no antibodies blocking ACT-receptor binding, such as M1H5 or M2B10, have been previously described.
A barrier to development of additional technologies based on ACT has been the challenges of recovering monomeric protein from in vitro refolding processes. Standard protocols, including dilution and dialysis from denaturing buffers containing 8 M urea recover high molecular weight species with variable activity levels. Recently, refolding on a size exclusion column was performed to prevent aggregation of partially folded species and resulted in purification of monomers with very high activity, dependent on the presence of calcium and acylation and molecular confinement (43). While promising, the yields and scalability of this process are currently unclear. As shown here, the RTX domain presents an alternative to ACT that retains many structural features, is more readily expressed and exhibits greater stability. Furthermore, since RTX lacks the catalytic domain, it has no homology to endogenous proteins and thus poses no potential autoimmunity concerns for human use. We evaluated two different RTX constructs, initially RTX985 lacking the acylation sites and thus simpler to express and then the larger RTX751* retaining the acylation sites. While both exhibited expected calcium dependent structural shifts and binding to previously described monoclonal antibodies, RTX751* appears superior to RTX985 in terms of monomericity, stability and recognition of soluble αMβ2 receptor in vitro.
Since RTX985 is well behaved and binds at least one neutralizing antibody (M2B10), we used this construct for immunization before discovering that RTX751 and RTX751* are better behaved and retain the ability to bind both neutralizing antibodies. Regardless, sera from mice immunized with RTX985 neutralized cAMP intoxication in vitro as efficiently as sera from ACT-immunized mice (
RTX fragments are equally immunogenic as intact ACT and more immunogenic than the N-terminal catalytic and hydrophobic fragments (
An antibody that competes for binding to the repeat in toxin (RTX) domain of Bordetella adenylate cyclase toxin (ACT) with an antibody comprising sequences selected from the group consisting of: light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:1 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:2; light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:3 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:4; light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:5 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:6; light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:7 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:9; light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:9 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:10; and light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:11 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:12.
The antibody of embodiment P1, wherein the antibody comprises sequences selected from the group consisting of: light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:1 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:2; light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:3 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:4; light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:5 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:6; light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:7 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:9; light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:9 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:10; and light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:11 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:12.
The antibody of embodiment P1 or P2, wherein the antibody comprises sequences selected from the group consisting of: light chain variable region sequence of SEQ ID NO:1 and heavy chain variable region sequence of SEQ ID NO:2; light chain variable region sequence of SEQ ID NO:3 and heavy chain variable region sequence of SEQ ID NO:4; light chain variable region sequence of SEQ ID NO:5 and heavy chain variable region sequence of SEQ ID NO:6; light chain variable region sequence of SEQ ID NO:7 and heavy chain variable region sequence of SEQ ID NO:9; light chain variable region sequence of SEQ ID NO:9 and heavy chain variable region sequence of SEQ ID NO:10; and light chain variable region sequence of SEQ ID NO:11 and heavy chain variable region sequence of SEQ ID NO:12.
An antibody that competes for binding to the repeat in toxin (RTX) domain of Bordetella adenylate cyclase toxin (ACT) with an antibody comprising sequences selected from the group consisting of: light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:13 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:14; light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:15 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:16; and light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:17 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:18.
The antibody of embodiment P4, wherein the antibody comprises sequences selected from the group consisting of: light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:13 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:14; light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:15 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:16; and light chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:17 and heavy chain CDR1, CDR2, and CDR3 sequences of SEQ ID NO:18.
The antibody of embodiment P4 or P5, wherein the antibody comprises sequences selected from the group consisting of: light chain variable region sequence of SEQ ID NO:13 and heavy chain variable region sequence of SEQ ID NO:14; light chain variable region sequence of SEQ ID NO:15 and heavy chain variable region sequence of SEQ ID NO:16; and light chain variable region sequence of SEQ ID NO:17 and heavy chain variable region sequence of SEQ ID NO:18.
The antibody of any one of the foregoing embodiments, wherein the antibody is humanized.
The antibody of any one of the foregoing embodiments, wherein the antibody is a single chain antibody (scAb).
The antibody of embodiment P8, wherein the scAb comprises a light chain variable region, a linker consisting of 4-40 amino acids, and a heavy chain variable region.
The antibody of embodiment P8 or P9, wherein the scAb further comprises a constant region.
The antibody of any one of embodiments P8-P10, wherein the linker consists of 16-24 amino acids.
The antibody of any one of the foregoing embodiments, further comprising a detectable label.
A pharmaceutical composition comprising the antibody of any one of the foregoing embodiments and a pharmaceutically acceptable excipient.
The pharmaceutical composition of embodiment P13, comprising at least one additional antibody specific for the RTX domain.
A method of treating an individual exposed to Bordetella bacteria comprising administering the pharmaceutical composition of any one of embodiments P13-P14 to the individual, thereby treating the individual.
A vaccine composition comprising a recombinant Bordetella adenylate cyclase toxin polypeptide consisting essentially of a sequence corresponding to amino acid residues 700-1706 of Bordetella adenylate cyclase toxin protein or an immunogenic fragment thereof and a pharmaceutically acceptable vaccine excipient.
The vaccine composition of embodiment 1, wherein said recombinant Bordetella adenylate cyclase toxin polypeptide consists of a sequence corresponding to amino acid residues 700-1706 of Bordetella adenylate cyclase toxin protein or an immunogenic fragment thereof and a pharmaceutically acceptable vaccine excipient.
The vaccine composition of embodiment 1 or 2, wherein said sequence corresponds to amino acid residues 751-1706 of Bordetella adenylate cyclase toxin protein or a fragment thereof.
The vaccine composition of one of embodiments 1-3, wherein said sequence corresponds to amino acid residues 985-1706 of Bordetella adenylate cyclase toxin protein or a fragment thereof.
The vaccine composition of one of embodiments 1-4, wherein said sequence corresponds to amino acid residues 1000-1706 of Bordetella adenylate cyclase toxin protein or a fragment thereof.
The vaccine composition of one of embodiments 1-5, wherein said sequence is SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37 or SEQ ID NO:38.
The vaccine composition of one of embodiments 1-6, wherein said sequence comprises an acylated amino acid residue.
The vaccine composition of embodiment 7, wherein said sequence comprises an acylated amino acid residue at a position corresponding to K983 or K860.
The vaccine composition of embodiment 7, wherein said acylated residue is a lysine.
The vaccine composition of one of embodiments 1-9, wherein said Bordetella adenylate cyclase toxin polypeptide binds αMβ2 integrin.
The vaccine composition of one of embodiments 1-6, wherein said sequence is a non-acylated sequence.
The vaccine composition of one of embodiments 1-6 or 11, wherein said sequence comprises a non-acylated amino acid residue at a position corresponding to K983 or K860.
The vaccine composition of embodiment 11, wherein said non-acylated residue is a lysine.
The vaccine composition of one of embodiments 11-13, wherein said Bordetella adenylate cyclase toxin polypeptide does not bind αMβ2 integrin.
The vaccine composition of one of embodiments 1-14, further comprising an adjuvant.
A method for immunizing a subject in need thereof against Bordetella pertussis, the method comprising administering to said subject an effective amount of the vaccine of one of embodiments 1-15.
A method of preventing or treating whooping cough in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of the vaccine of one of embodiments 1-15.
This application claims the benefit of U.S. Provisional Patent Application No. 62/089,000, filed Dec. 8, 2014, which is incorporated herein by reference in its entirety and for all purposes.
This invention was made with government support under GM095638 awarded by the National Institutes of Health. The Government has certain rights in the invention. This work was further supported by a grant from the Welch Foundation (Grant No. F-1767).
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US15/64547 | 12/8/2015 | WO | 00 |
| Number | Date | Country | |
|---|---|---|---|
| 62089000 | Dec 2014 | US |
